U.S. patent application number 14/848452 was filed with the patent office on 2016-01-07 for anti-asic1 antibodies and uses thereof.
The applicant listed for this patent is Regeneron Pharmaceuticals, Inc.. Invention is credited to Nicole M. Alessandri-Haber, Min Gao, Michael L. LaCroix-Fralish, Lynn MacDonald, Marc R. Morra.
Application Number | 20160002332 14/848452 |
Document ID | / |
Family ID | 47666522 |
Filed Date | 2016-01-07 |
United States Patent
Application |
20160002332 |
Kind Code |
A1 |
MacDonald; Lynn ; et
al. |
January 7, 2016 |
Anti-ASIC1 Antibodies and Uses Thereof
Abstract
The present invention provides antibodies and antigen-binding
fragments thereof that specifically bind to cells expressing
acid-sensing ion channel-1 (ASIC1). According to certain
embodiments of the invention, the antibodies inhibit acid-induced,
ASIC1-mediated ion currents in cells expressing human ASIC1. The
antibodies of the invention are useful for the treatment of pain,
including pain associated with surgical intervention and various
diseases and disorders.
Inventors: |
MacDonald; Lynn; (White
Plains, NY) ; Gao; Min; (Montvale, NJ) ;
Morra; Marc R.; (Beacon Falls, CT) ;
Alessandri-Haber; Nicole M.; (Rye, NY) ;
LaCroix-Fralish; Michael L.; (Yorktown Heights, NY) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Regeneron Pharmaceuticals, Inc. |
Tarrytown |
NY |
US |
|
|
Family ID: |
47666522 |
Appl. No.: |
14/848452 |
Filed: |
September 9, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13753836 |
Jan 30, 2013 |
9150648 |
|
|
14848452 |
|
|
|
|
61592837 |
Jan 31, 2012 |
|
|
|
61692925 |
Aug 24, 2012 |
|
|
|
61644038 |
May 8, 2012 |
|
|
|
Current U.S.
Class: |
530/387.9 |
Current CPC
Class: |
C07K 2317/565 20130101;
C12N 15/00 20130101; A61K 39/00 20130101; C07K 2317/92 20130101;
C07K 16/28 20130101; C07K 2317/21 20130101; A61P 25/04 20180101;
A61P 35/00 20180101; A61P 29/00 20180101; A61K 2039/505 20130101;
C07K 16/18 20130101; C07K 2317/76 20130101; A61P 25/06 20180101;
C07K 2317/56 20130101; C12N 5/00 20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28 |
Claims
1. An isolated antibody or antigen-binding fragment thereof that
specifically binds cell surface-expressed acid sensing ion channel
1 (ASIC1) (SEQ ID NO:401).
2. The antibody or antigen-binding fragment of claim 1, wherein the
antibody or antigen-binding fragment thereof specifically binds
cell surface-expressed ASIC1 with an EC.sub.50 of 1 nM or less as
measured using fluorescence activated cell sorting (FACS).
3. The antibody or antigen-binding fragment of claim 1, wherein the
antibody or antigen-binding fragment thereof inhibits acid-induced,
ASIC1-mediated ion currents in cells expressing human ASIC1.
4. The antibody or antigen-binding fragment of claim 3, wherein the
antibody or antigen-binding fragment thereof inhibits acid-induced
cellular calcium flux in cells expressing ASIC1 at pH of about 5.0
to about 6.0 with an IC.sub.50 of 6 nM or less as measured using a
FLIPR assay.
5. The antibody or antigen-binding fragment of claim 3, wherein the
antibody or antigen-binding fragment thereof inhibits acid-induced
ion currents at pH of about 5.0 to about 6.0 with an IC.sub.50 of
10 nM or less as measured using a patch-clamp assay.
6. The antibody or antigen-binding fragment of claim 5, wherein the
antibody or antigen-binding fragment thereof comprises: (a) three
complementarity determining regions (CDRs) of a heavy chain
variable region (HCVR) having an amino acid sequence selected from
the group consisting of SEQ ID NOs: 2, 34, 50, 66, 114, 130, 146,
162, 194, 210, 242, 258, and 274; and (b) three CDRs of a light
chain variable region (LCVR) having an amino acid sequence selected
from the group consisting of SEQ ID NOs: 10, 42, 58, 74, 122, 138,
154, 170, 202, 218, 250, 266, and 282.
7. The antibody or antigen-binding fragment of claim 6, wherein the
antibody or antigen-binding fragment thereof comprises a HCVR/LCVR
amino acid sequence pair selected from the group consisting of: SEQ
ID NOs: 2/10; 34/42; 50/58; 66/74; 114/122; 130/138; 146/154;
162/170; 194/202; 210/218; 242/250; 258/266; and 274/282.
8. The antibody or antigen-binding fragment of claim 7, wherein the
antibody or antigen-binding fragment thereof comprises
HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected
from the group consisting of: SEQ ID NOs: 4-6-8-12-14-16;
36-38-40-44-46-48; 52-54-56-60-62-64; 68-70-72-76-78-80;
116-118-120-124-126-128; 132-134-136-140-142-144;
148-150-152-156-158-160; 164-166-168-172-174-176;
196-198-200-204-206-208; 212-214-216-220-222-224;
244-246-248-252-254-256; 260-262-264-268-270-272; and
276-278-280-284-286-288.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 13/753,836 filed on Jan. 30, 2013, entitled
"Anti-ASIC1 Antibodies and Uses Thereof," which claims priority to
35 U.S.C. .sctn.119(e) of US provisional application Nos.
61/592,837, filed on Jan. 31, 2012; 61/644,038, filed on May 8,
2012; and 61/692,925, filed on Aug. 24, 2012, the disclosures of
which are herein incorporated by reference in their entireties.
FIELD OF THE INVENTION
[0002] The present invention relates to antibodies, and
antigen-binding fragments thereof, which are specific for human
ASIC1, and methods of use thereof.
BACKGROUND
[0003] Acid sensing ion channels (ASICs) are proton-gated cationic
channels expressed in the central and peripheral nervous systems.
The ASIC family in humans includes ASIC1, ASIC2, ASIC3 and ASIC4
subunits which arrange into homo- or heteromultimeric ion channels
in neuronal membranes. ASIC1, ASIC2 and ASIC3 are significantly
expressed in the small and medium nociceptive sensory neurons that
are able to detect noxious chemical, thermal, and high threshold
mechanical stimuli. ASIC2 and ASIC3 are also expressed in large
neurons that mostly correspond to low threshold
mechanoreceptors.
[0004] ASICs are permeable to Na.sup.+ and Ca.sup.2+ ions and are
activated by external pH variations ranging from pH 6.8 to 4.0.
ASICs are believed to play an important role in sensing local
acidosis. Local tissue acidosis is a hallmark of pain and
inflammation, and inflamed tissues frequently exhibit low pH (as
low as .about.4.7). Blockage of ASICs has been proposed as a method
for treating a variety of disorders and conditions. Blockage of
ASIC1 in particular has been proposed as a means for treating
conditions such as pain, neurodegenerative diseases, and
psychiatric diseases.
[0005] Pharmacologic inhibitors of ASIC1 include the tarantula
peptide Psalmotoxin-1 (PcTx1) which specifically inhibits ASIC1
homomers, and the small molecule, non-selective ASIC inhibitors
amiloride and A-317567. The 40 amino acid peptide toxin APETx2,
isolated from sea anemone, has been shown to inhibit ASIC3 homomers
as well as ASIC3/1 and ASIC3/2 heteromers.
[0006] Currently, there are no known antibodies that specifically
block ASICs. Thus, there is a need in the art for novel ASIC
inhibitors, such as anti-ASIC1 antibodies, that can be used to
treat diseases and conditions mediated by ASIC signaling.
BRIEF SUMMARY OF THE INVENTION
[0007] The present invention provides antibodies that specifically
bind human ASIC1, including, e.g., antibodies that specifically
bind cell surface-expressed ASIC1. The antibodies of the present
invention, according to certain embodiments, inhibit acid-induced,
ASIC1-mediated ion currents in cells expressing human ASIC1. The
antibodies of the invention are useful, inter alia, for inhibiting
ASIC1-mediated signaling and for treating diseases and disorders
caused by or related to ASIC1 activity and/or signaling. For
example, the antibodies of the present invention can be
administered to a patient for the treatment or alleviation of pain
and related conditions.
[0008] The antibodies of the invention can be full-length (for
example, an IgG1 or IgG4 antibody) or may comprise only an
antigen-binding portion (for example, a Fab, F(ab').sub.2 or scFv
fragment), and may be modified to affect functionality, e.g., to
eliminate residual effector functions (Reddy et al., 2000, J.
Immunol. 164:1925-1933).
[0009] The present invention provides an antibody or
antigen-binding fragment of an antibody comprising a heavy chain
variable region (HCVR) having an amino acid sequence selected from
the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114,
130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322,
338, 354, 370, and 386, or a substantially similar sequence thereof
having at least 90%, at least 95%, at least 98% or at least 99%
sequence identity.
[0010] The present invention also provides an antibody or
antigen-binding fragment of an antibody comprising a light chain
variable region (LCVR) having an amino acid sequence selected from
the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106,
122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314,
330, 346, 362, 378, and 394, or a substantially similar sequence
thereof having at least 90%, at least 95%, at least 98% or at least
99% sequence identity.
[0011] The present invention also provides an antibody or
antigen-binding fragment thereof comprising a HCVR and LCVR
(HCVR/LCVR) sequence pair selected from the group consisting of SEQ
ID NO: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122,
130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234,
242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346,
354/362, 370/378, and 386/394.
[0012] The present invention also provides an antibody or
antigen-binding fragment of an antibody comprising a heavy chain
CDR3 (HCDR3) domain having an amino acid sequence selected from the
group consisting of SEQ ID NO: 8, 24, 40, 56, 72, 88, 104, 120,
136, 152, 168, 184, 200, 216, 232, 248, 264, 280, 296, 312, 328,
344, 360, 376, and 392, or a substantially similar sequence thereof
having at least 90%, at least 95%, at least 98% or at least 99%
sequence identity; and a light chain CDR3 (LCDR3) domain having an
amino acid sequence selected from the group consisting of SEQ ID
NO: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224,
240, 256, 272, 288, 304, 320, 336, 352, 368, 384, and 400, or a
substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity.
[0013] In certain embodiments, the antibody or antigen-binding
portion of an antibody comprises a HCDR3/LCDR3 amino acid sequence
pair selected from the group consisting of SEQ ID NO: 8/16, 24/32,
40/48, 56/64, 72/80, 88/96, 104/112, 120/128, 136/144, 152/160,
168/176, 184/192, 200/208, 216/224, 232/240, 248/256, 264/272,
280/288, 296/304, 312/320, 328/336, 344/352, 360/368, 376/384, and
392/400.
[0014] The present invention also provides an antibody or fragment
thereof further comprising a heavy chain CDR1 (HCDR1) domain having
an amino acid sequence selected from the group consisting of SEQ ID
NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212,
228, 244, 260, 276, 292, 308, 324, 340, 356, 372, and 388, or a
substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity; a heavy
chain CDR2 (HCDR2) domain having an amino acid sequence selected
from the group consisting of SEQ ID NO: 6, 22, 38, 54, 70, 86, 102,
118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, 310,
326, 342, 358, 374, and 390, or a substantially similar sequence
thereof having at least 90%, at least 95%, at least 98% or at least
99% sequence identity; a light chain CDR1 (LCDR1) domain having an
amino acid sequence selected from the group consisting of SEQ ID
NO: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220,
236, 252, 268, 284, 300, 316, 332, 348, 364, 380, and 396, or a
substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity; and a
light chain CDR2 (LCDR2) domain having an amino acid sequence
selected from the group consisting of SEQ ID NO: 14, 30, 46, 62,
78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286,
302, 318, 334, 350, 366, 382, and 398, or a substantially similar
sequence thereof having at least 90%, at least 95%, at least 98% or
at least 99% sequence identity.
[0015] Certain non-limiting, exemplary antibodies and
antigen-binding fragments of the invention comprise
HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, having
the amino acid sequences selected from the group consisting of: SEQ
ID NOs: 4-6-8-12-14-16 (e.g. H1M6712N); 20-22-24-28-30-32 (e.g.
H1M6716N); 36-38-40-44-46-48 (e.g. H1M6718N); 52-54-56-60-62-64
(e.g. H1M7101N); 68-70-72-76-78-80 (e.g. H2M7103N);
84-86-88-92-94-96 (e.g. H3M6713N); 100-102-104-108-110-112 (e.g.
H3M6715N); 116-118-120-124-126-128 (e.g. H3M6720N);
132-134-136-140-142-144 (e.g. H3M6721 N); 148-150-152-156-158-160
(e.g., H3M6721 N2); 164-166-168-172-174-176 (e.g. H3M6726N);
180-182-184-188-190-192 (e.g., H3M6760N); 196-198-200-204-206-208
(e.g. H3M7102N); 212-214-216-220-222-224 (e.g. H3M7118N);
228-230-232-236-238-240 (e.g. H4H6362P); 244-246-248-252-254-256
(e.g. H4H6363P); 260-262-264-268-270-272 (e.g. H4H6364P);
276-278-280-284-286-288 (e.g. H4H6366P); 292-294-296-300-302-304
(e.g. H4H6372P); 308-310-312-316-318-320 (e.g. H4H6374P);
324-326-328-332-334-336 (e.g. H4H6375P); 340-342-344-348-350-352
(e.g. H4H6379P); 356-358-360-364-366-368 (e.g. H4H6380P);
372-374-376-380-382-384 (e.g. H4H6381P); and
388-390-392-396-398-400 (e.g. H4H6383P).
[0016] In a related embodiment, the invention includes an antibody
or antigen-binding fragment of an antibody which specifically binds
ASIC1 (e.g., cell surface-expressed ASIC1), wherein the antibody or
fragment comprises the heavy and light chain CDR domains contained
within heavy and light chain variable region (HCVR/LCVR) sequences
selected from the group consisting of SEQ ID NO: 2/10, 18/26,
34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154,
162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266,
274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 370/378, and
386/394. Methods and techniques for identifying CDRs within HCVR
and LCVR amino acid sequences are well known in the art and can be
used to identify CDRs within the specified HCVR and/or LCVR amino
acid sequences disclosed herein. Exemplary conventions that can be
used to identify the boundaries of CDRs include, e.g., the Kabat
definition, the Chothia definition, and the AbM definition. In
general terms, the Kabat definition is based on sequence
variability, the Chothia definition is based on the location of the
structural loop regions, and the AbM definition is a compromise
between the Kabat and Chothia approaches. See, e.g., Kabat,
"Sequences of Proteins of Immunological Interest," National
Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J.
Mol. Biol. 273:927-948 (1997); and Martin et al., Proc. Natl. Acad.
Sci. USA 86:9268-9272 (1989). Public databases are also available
for identifying CDR sequences within an antibody.
[0017] In another aspect, the invention provides nucleic acid
molecules encoding anti-ASIC1 antibodies or fragments thereof.
Recombinant expression vectors carrying the nucleic acids of the
invention, and host cells into which such vectors have been
introduced, are also encompassed by the invention, as are methods
of producing the antibodies by culturing the host cells under
conditions permitting production of the antibodies, and recovering
the antibodies produced.
[0018] In one embodiment, the invention provides an antibody or
fragment thereof comprising a HCVR encoded by a nucleic acid
sequence selected from the group consisting of SEQ ID NO: 1, 17,
33, 49, 65, 81, 97, 113, 129, 145, 161, 177, 193, 209, 225, 241,
257, 273, 289, 305, 321, 337, 353, 369, and 385, or a substantially
identical sequence having at least 90%, at least 95%, at least 98%,
or at least 99% homology thereof.
[0019] The present invention also provides an antibody or fragment
thereof comprising a LCVR encoded by a nucleic acid sequence
selected from the group consisting of SEQ ID NO: 9, 25, 41, 57, 73,
89, 105, 121, 137, 153, 169, 185, 201, 217, 233, 249, 265, 281,
297, 313, 329, 345, 361, 377, and 393, or a substantially identical
sequence having at least 90%, at least 95%, at least 98%, or at
least 99% homology thereof.
[0020] The present invention also provides an antibody or
antigen-binding fragment of an antibody comprising a HCDR3 domain
encoded by a nucleotide sequence selected from the group consisting
of SEQ ID NO: 7, 23, 39, 55, 71, 87, 103, 119, 135, 151, 167, 183,
199, 215, 231, 247, 263, 279, 295, 311, 327, 343, 359, 375, and
391, or a substantially identical sequence having at least 90%, at
least 95%, at least 98%, or at least 99% homology thereof; and a
LCDR3 domain encoded by a nucleotide sequence selected from the
group consisting of SEQ ID NO: 15, 31, 47, 63, 79, 95, 111, 127,
143, 159, 175, 191, 207, 223, 239, 255, 271, 287, 303, 319, 335,
351, 367, 383, and 399, or a substantially identical sequence
having at least 90%, at least 95%, at least 98%, or at least 99%
homology thereof.
[0021] The present invention also provides an antibody or fragment
thereof which further comprises a HCDR1 domain encoded by a
nucleotide sequence selected from the group consisting of SEQ ID
NO: 3, 19, 35, 51, 67, 83, 99, 115, 131, 147, 163, 179, 195, 211,
227, 243, 259, 275, 291, 307, 323, 339, 355, 371, and 387, or a
substantially identical sequence having at least 90%, at least 95%,
at least 98%, or at least 99% homology thereof; a HCDR2 domain
encoded by a nucleotide sequence selected from the group consisting
of SEQ ID NO: 5, 21, 37, 53, 69, 85, 101, 117, 133, 149, 165, 181,
197, 213, 229, 245, 261, 277, 293, 309, 325, 341, 357, 373, and
389, or a substantially identical sequence having at least 90%, at
least 95%, at least 98%, or at least 99% homology thereof; a LCDR1
domain encoded by a nucleotide sequence selected from the group
consisting of SEQ ID NO: 11, 27, 43, 59, 75, 91, 107, 123, 139,
155, 171, 187, 203, 219, 235, 251, 267, 283, 299, 315, 331, 347,
363, 379, and 395, or a substantially identical sequence having at
least 90%, at least 95%, at least 98%, or at least 99% homology
thereof; and a LCDR2 domain encoded by a nucleotide sequence
selected from the group consisting of SEQ ID NO: 13, 29, 45, 61,
77, 93, 109, 125, 141, 157, 173, 189, 205, 221, 237, 253, 269, 285,
301, 317, 333, 349, 365, 381, and 397, or a substantially identical
sequence having at least 90%, at least 95%, at least 98%, or at
least 99% homology thereof.
[0022] According to certain embodiments, the antibody or fragment
thereof comprises the heavy and light chain CDR sequences encoded
by the nucleic acid sequences of SEQ ID NOs: 1 and 9 (e.g.
H1M6712N), 17 and 25 (e.g. H1M6716N), 33 and 41 (e.g. H1M6718N), 49
and 57 (e.g. H1M7101N), 65 and 73 (e.g. H2M7103N), 81 and 89 (e.g.
H3M6713N), 97 and 105 (e.g. H3M6715N), 113 and 121 (e.g. H3M6720N),
129 and 137 (e.g. H3M6721N), 145 and 153 (e.g. H3M6721N2), 161 and
169 (e.g. H3M6726N), 177 and 185 (e.g. H3M6760N), 193 and 201 (e.g.
H3M7102N), 209 and 217 (e.g. H3M7118N), 225 and 233 (e.g.
H4H6362P), 241 and 249 (e.g. H4H6363P), 257 and 265 (e.g.
H4H6364P), 273 and 281 (e.g. H4H6366P), 289 and 297 (e.g.
H4H6372P), 305 and 313 (e.g. H4H6374P), 321 and 329 (e.g.
H4H6375P), 337 and 345 (e.g. H4H6379P), 353 and 361 (e.g.
H4H6380P), 369 and 377 (e.g. H4H6381P), 385 and 393 (e.g.
H4H6383P).
[0023] The present invention includes anti-ASIC1 antibodies having
a modified glycosylation pattern. In some applications,
modification to remove undesirable glycosylation sites may be
useful, or an antibody lacking a fucose moiety present on the
oligosaccharide chain.
[0024] In another aspect, the invention provides a pharmaceutical
composition comprising a recombinant human antibody or fragment
thereof which specifically binds ASIC1 (e.g., cell
surface-expressed ASIC1) and a pharmaceutically acceptable carrier.
In a related aspect, the invention features a composition which is
a combination of an anti-ASIC1 antibody and a second therapeutic
agent. In one embodiment, the second therapeutic agent is any agent
that is advantageously combined with an anti-ASIC1 antibody.
Exemplary agents that may be advantageously combined with an
anti-ASIC1 antibody include, without limitation, other agents that
inhibit ASIC1 activity (including other antibodies or
antigen-binding fragments thereof, peptide inhibitors, small
molecule antagonists, etc.) and/or agents which do not directly
bind ASIC1 but nonetheless interfere with, block or attenuate
ASIC1-mediated ion currents in cells.
[0025] In yet another aspect, the invention provides methods for
inhibiting ASIC1-mediated ion currents using an anti-ASIC1 antibody
or antigen-binding portion of an antibody of the invention, wherein
the therapeutic methods comprise administering a therapeutically
effective amount of a pharmaceutical composition comprising an
antibody or antigen-binding fragment of an antibody of the
invention. The disorder treated is any disease or condition which
is improved, ameliorated, inhibited or prevented by removal,
inhibition or reduction of ASIC1-mediated ion currents. The
anti-ASIC1 antibodies or antibody fragments of the invention may
function to block acid-induced ASIC1-mediated currents, or
otherwise inhibit the signaling activity of ASIC1.
[0026] The present invention also includes the use of an anti-ASIC1
antibody or antigen binding portion of an antibody of the invention
in the manufacture of a medicament for the treatment of a disease
or disorder related to or caused by ASIC1-mediated ion currents in
a patient.
[0027] Other embodiments will become apparent from a review of the
ensuing detailed description.
BRIEF DESCRIPTION OF THE FIGURES
[0028] FIG. 1 depicts the withdrawal thresholds of mice treated
with an anti-ASIC1 antibody (H1M6718N), or isotype control
antibody, in response to a mechanical pinch of the tail (panel A)
or the gastrocnemius muscle (panel B). Results are expressed in
terms of withdrawal threshold to the pinch in grams (mean.+-.SEM
for each cohort of mice).
[0029] FIG. 2 shows the percent change in the withdrawal threshold
from baseline in acidic saline-induced muscle hyperalgesia in mice
treated with an anti-ASIC1 antibody (H1M6718N) or isotype
control.
[0030] FIG. 3 (panels A and B) show the percent change in the
withdrawal threshold from baseline in carrageenan-induced muscle
hyperalgesia in mice treated with anti-ASIC1 antibody (H1M6718N, 10
or 40 mg/kg--panel A; or H4H6721 N2 10 or 30 mg/kg--panel B), or
isotype control.
[0031] FIG. 4 shows the extent of taxol-induced tactile allodynia
over time in taxol-administered mice that were treated with either
30 mg/kg (s.c.) of an isotype control antibody, 30 mg/kg (s.c.) of
H1M6718N, or 100 mg/kg (s.c.) of gabapentin. Results are expressed
in terms of withdrawal threshold (g) as measured using Von Frey
fibers (as described in Example 10).
DETAILED DESCRIPTION
[0032] Before the present invention is described, it is to be
understood that this invention is not limited to particular methods
and experimental conditions described, as such methods and
conditions may vary. It is also to be understood that the
terminology used herein is for the purpose of describing particular
embodiments only, and is not intended to be limiting, since the
scope of the present invention will be limited only by the appended
claims.
[0033] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. As used
herein, the term "about," when used in reference to a particular
recited numerical value, means that the value may vary from the
recited value by no more than 1%. For example, as used herein, the
expression "about 100" includes 99 and 101 and all values in
between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0034] Although any methods and materials similar or equivalent to
those described herein can be used in the practice or testing of
the present invention, the preferred methods and materials are now
described. All patents, applications and non-patent publications
mentioned in this specification are incorporated herein by
reference in their entireties.
DEFINITIONS
[0035] The expressions "ASIC1" and "ASIC1 fragment," as used herein
refer to the human ASIC1 protein or fragment unless specified as
being from a non-human species (e.g., "mouse ASIC1," "mouse ASIC1
fragment," "monkey ASIC1," "monkey ASIC1 fragment," etc.). Human
ASIC1 has the amino acid sequence as set forth in SEQ ID NO:401).
The expression "ASIC1," as used herein, includes soluble fragments
of the ASIC1 extracellular domain (e.g., polypeptides comprising or
consisting of at least 30 contiguous amino acids found within amino
acids 63 to 424 of SEQ ID NO:401), as well as cell
surface-expressed ASIC1 (as that term is defined herein below).
[0036] As used herein, "an antibody that binds ASIC1" or an
"anti-ASIC1 antibody" includes antibodies, and antigen-binding
fragments thereof, that bind a soluble fragment of an ASIC1 protein
(e.g., a portion of the extracellular domain of ASIC1) and/or cell
surface-expressed ASIC1. The expression "cell surface-expressed
ASIC1" means one or more ASIC1 protein(s) that is/are expressed on
the surface of a cell in vitro or in vivo, such that at least a
portion of the ASIC1 protein (e.g., amino acids 63 to 424 of SEQ ID
NO:401) is exposed to the extracellular side of the cell membrane
and accessible to an antigen-binding portion of an antibody. "Cell
surface-expressed ASIC1" includes ASIC1 protein contained within
the context of a functional ASIC1 ion channel in the membrane of a
cell. In some instances, "cell surface-expressed ASIC1" is an ASIC1
protein that is expressed as part of a heteromultimer on the
surface of a cell (e.g., an ASIC1/2, ASIC1/3 or ASIC1/4
heteromultimer). In other instances, "cell surface-expressed ASIC1"
is an ASIC1 protein that is expressed as part of a homomultimer on
the surface of a cell. Moreover, "cell surface-expressed ASIC1" can
comprise or consist of ASIC1 protein expressed on the surface of a
cell which normally expressed ASIC1 protein. Alternatively, "cell
surface-expressed ASIC1" can comprise or consist of ASIC1 protein
expressed on the surface of a cell that normally does not express
human ASIC1 on its surface but has been artificially engineered to
express ASIC1 on its surface.
[0037] The term "antibody", as used herein, means any
antigen-binding molecule or molecular complex comprising at least
one complementarity determining region (CDR) that specifically
binds to or interacts with a particular antigen (e.g., ASIC1). The
term "antibody" includes immunoglobulin molecules comprising four
polypeptide chains, two heavy (H) chains and two light (L) chains
inter-connected by disulfide bonds, as well as multimers thereof
(e.g., IgM). Each heavy chain comprises a heavy chain variable
region (abbreviated herein as HCVR or V.sub.H) and a heavy chain
constant region. The heavy chain constant region comprises three
domains, C.sub.H1, C.sub.H2 and C.sub.H3. Each light chain
comprises a light chain variable region (abbreviated herein as LCVR
or V.sub.L) and a light chain constant region. The light chain
constant region comprises one domain (C.sub.L1). The V.sub.H and
V.sub.L regions can be further subdivided into regions of
hypervariability, termed complementarity determining regions
(CDRs), interspersed with regions that are more conserved, termed
framework regions (FR). Each V.sub.H and V.sub.L is composed of
three CDRs and four FRs, arranged from amino-terminus to
carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3,
CDR3, FR4. In different embodiments of the invention, the FRs of
the anti-ASIC1 antibody (or antigen-binding portion thereof) may be
identical to the human germline sequences, or may be naturally or
artificially modified. An amino acid consensus sequence may be
defined based on a side-by-side analysis of two or more CDRs.
[0038] The term "antibody", as used herein, also includes
antigen-binding fragments of full antibody molecules. The terms
"antigen-binding portion" of an antibody, "antigen-binding
fragment" of an antibody, and the like, as used herein, include any
naturally occurring, enzymatically obtainable, synthetic, or
genetically engineered polypeptide or glycoprotein that
specifically binds an antigen to form a complex. Antigen-binding
fragments of an antibody may be derived, e.g., from full antibody
molecules using any suitable standard techniques such as
proteolytic digestion or recombinant genetic engineering techniques
involving the manipulation and expression of DNA encoding antibody
variable and optionally constant domains. Such DNA is known and/or
is readily available from, e.g., commercial sources, DNA libraries
(including, e.g., phage-antibody libraries), or can be synthesized.
The DNA may be sequenced and manipulated chemically or by using
molecular biology techniques, for example, to arrange one or more
variable and/or constant domains into a suitable configuration, or
to introduce codons, create cysteine residues, modify, add or
delete amino acids, etc.
[0039] Non-limiting examples of antigen-binding fragments include:
(i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv)
Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb
fragments; and (vii) minimal recognition units consisting of the
amino acid residues that mimic the hypervariable region of an
antibody (e.g., an isolated complementarity determining region
(CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4
peptide. Other engineered molecules, such as domain-specific
antibodies, single domain antibodies, domain-deleted antibodies,
chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies,
tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies,
bivalent nanobodies, etc.), small modular immunopharmaceuticals
(SMIPs), and shark variable IgNAR domains, are also encompassed
within the expression "antigen-binding fragment," as used
herein.
[0040] An antigen-binding fragment of an antibody will typically
comprise at least one variable domain. The variable domain may be
of any size or amino acid composition and will generally comprise
at least one CDR which is adjacent to or in frame with one or more
framework sequences. In antigen-binding fragments having a V.sub.H
domain associated with a V.sub.L domain, the V.sub.H and V.sub.L
domains may be situated relative to one another in any suitable
arrangement. For example, the variable region may be dimeric and
contain V.sub.H-V.sub.H, V.sub.H-V.sub.L or V.sub.L-V.sub.L dimers.
Alternatively, the antigen-binding fragment of an antibody may
contain a monomeric V.sub.H or V.sub.L domain.
[0041] In certain embodiments, an antigen-binding fragment of an
antibody may contain at least one variable domain covalently linked
to at least one constant domain. Non-limiting, exemplary
configurations of variable and constant domains that may be found
within an antigen-binding fragment of an antibody of the present
invention include: (i) V.sub.H-C.sub.H1; (ii) V.sub.H-C.sub.H2;
(iii) V.sub.H-C.sub.H3; (iv) V.sub.H-C.sub.H1-C.sub.H2; (v)
V.sub.H-C.sub.H1-C.sub.H2-C.sub.H3, (vi) V.sub.H-C.sub.H2-C.sub.H3;
(vii) V.sub.L-C.sub.L; (viii) V.sub.L-C.sub.H1; (ix)
V.sub.L-C.sub.H2; (X) V.sub.L-C.sub.H3; (xi)
V.sub.L-C.sub.H1-C.sub.H2; (xii)
V.sub.L-C.sub.H1-C.sub.H2-C.sub.H3, (xiii)
V.sub.L-C.sub.H2-C.sub.H3; and (xiv) V.sub.L-C.sub.L. In any
configuration of variable and constant domains, including any of
the exemplary configurations listed above, the variable and
constant domains may be either directly linked to one another or
may be linked by a full or partial hinge or linker region. A hinge
region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or
more) amino acids which result in a flexible or semi-flexible
linkage between adjacent variable and/or constant domains in a
single polypeptide molecule. Moreover, an antigen-binding fragment
of an antibody of the present invention may comprise a homo-dimer
or hetero-dimer (or other multimer) of any of the variable and
constant domain configurations listed above in non-covalent
association with one another and/or with one or more monomeric
V.sub.H or V.sub.L domain (e.g., by disulfide bond(s)).
[0042] As with full antibody molecules, antigen-binding fragments
may be monospecific or multispecific (e.g., bispecific). A
multispecific antigen-binding fragment of an antibody will
typically comprise at least two different variable domains, wherein
each variable domain is capable of specifically binding to a
separate antigen or to a different epitope on the same antigen. Any
multispecific antibody format, including the exemplary bispecific
antibody formats disclosed herein, may be adapted for use in the
context of an antigen-binding fragment of an antibody of the
present invention using routine techniques available in the
art.
[0043] The term "human antibody", as used herein, is intended to
include antibodies having variable and constant regions derived
from human germline immunoglobulin sequences. The human antibodies
of the invention may include amino acid residues not encoded by
human germline immunoglobulin sequences (e.g., mutations introduced
by random or site-specific mutagenesis in vitro or by somatic
mutation in vivo), for example in the CDRs and in particular CDR3.
However, the term "human antibody", as used herein, is not intended
to include antibodies in which CDR sequences derived from the
germline of another mammalian species, such as a mouse, have been
grafted onto human framework sequences.
[0044] The term "recombinant human antibody", as used herein, is
intended to include all human antibodies that are prepared,
expressed, created or isolated by recombinant means, such as
antibodies expressed using a recombinant expression vector
transfected into a host cell (described further below), antibodies
isolated from a recombinant, combinatorial human antibody library
(described further below), antibodies isolated from an animal
(e.g., a mouse) that is transgenic for human immunoglobulin genes
(see e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295) or
antibodies prepared, expressed, created or isolated by any other
means that involves splicing of human immunoglobulin gene sequences
to other DNA sequences. Such recombinant human antibodies have
variable and constant regions derived from human germline
immunoglobulin sequences. In certain embodiments, however, such
recombinant human antibodies are subjected to in vitro mutagenesis
(or, when an animal transgenic for human Ig sequences is used, in
vivo somatic mutagenesis) and thus the amino acid sequences of the
V.sub.H and V.sub.L regions of the recombinant antibodies are
sequences that, while derived from and related to human germline
V.sub.H and V.sub.L sequences, may not naturally exist within the
human antibody germline repertoire in vivo.
[0045] Human antibodies can exist in two forms that are associated
with hinge heterogeneity. In one form, an immunoglobulin molecule
comprises a stable four chain construct of approximately 150-160
kDa in which the dimers are held together by an interchain heavy
chain disulfide bond. In a second form, the dimers are not linked
via inter-chain disulfide bonds and a molecule of about 75-80 kDa
is formed composed of a covalently coupled light and heavy chain
(half-antibody). These forms have been extremely difficult to
separate, even after affinity purification.
[0046] The frequency of appearance of the second form in various
intact IgG isotypes is due to, but not limited to, structural
differences associated with the hinge region isotype of the
antibody. A single amino acid substitution in the hinge region of
the human IgG4 hinge can significantly reduce the appearance of the
second form (Angal et al. (1993) Molecular Immunology 30:105) to
levels typically observed using a human IgG1 hinge. The instant
invention encompasses antibodies having one or more mutations in
the hinge, C.sub.H2 or C.sub.H3 region which may be desirable, for
example, in production, to improve the yield of the desired
antibody form.
[0047] An "isolated antibody," as used herein, means an antibody
that has been identified and separated and/or recovered from at
least one component of its natural environment. For example, an
antibody that has been separated or removed from at least one
component of an organism, or from a tissue or cell in which the
antibody naturally exists or is naturally produced, is an "isolated
antibody" for purposes of the present invention. An isolated
antibody also includes an antibody in situ within a recombinant
cell. Isolated antibodies are antibodies that have been subjected
to at least one purification or isolation step. According to
certain embodiments, an isolated antibody may be substantially free
of other cellular material and/or chemicals.
[0048] A "neutralizing" or "blocking" antibody, as used herein, is
intended to refer to an antibody whose binding to ASIC1 reduces or
detectably inhibits acid-induced ASIC1-mediated ion currents. The
inhibition caused by an ASIC1 neutralizing or blocking antibody
need not be complete so long as it is detectable using an
appropriate assay. Exemplary assays for detecting ASIC1 inhibition
are described elsewhere herein.
[0049] The anti-ASIC1 antibodies disclosed herein may comprise one
or more amino acid substitutions, insertions and/or deletions in
the framework and/or CDR regions of the heavy and light chain
variable domains as compared to the corresponding germline
sequences from which the antibodies were derived. Such mutations
can be readily ascertained by comparing the amino acid sequences
disclosed herein to germline sequences available from, for example,
public antibody sequence databases. The present invention includes
antibodies, and antigen-binding fragments thereof, which are
derived from any of the amino acid sequences disclosed herein,
wherein one or more amino acids within one or more framework and/or
CDR regions are mutated to the corresponding residue(s) of the
germline sequence from which the antibody was derived, or to the
corresponding residue(s) of another human germline sequence, or to
a conservative amino acid substitution of the corresponding
germline residue(s) (such sequence changes are referred to herein
collectively as "germline mutations"). A person of ordinary skill
in the art, starting with the heavy and light chain variable region
sequences disclosed herein, can easily produce numerous antibodies
and antigen-binding fragments which comprise one or more individual
germline mutations or combinations thereof. In certain embodiments,
all of the framework and/or CDR residues within the V.sub.H and/or
V.sub.L domains are mutated back to the residues found in the
original germline sequence from which the antibody was derived. In
other embodiments, only certain residues are mutated back to the
original germline sequence, e.g., only the mutated residues found
within the first 8 amino acids of FR1 or within the last 8 amino
acids of FR4, or only the mutated residues found within CDR1, CDR2
or CDR3. In other embodiments, one or more of the framework and/or
CDR residue(s) are mutated to the corresponding residue(s) of a
different germline sequence (i.e., a germline sequence that is
different from the germline sequence from which the antibody was
originally derived). Furthermore, the antibodies of the present
invention may contain any combination of two or more germline
mutations within the framework and/or CDR regions, e.g., wherein
certain individual residues are mutated to the corresponding
residue of a particular germline sequence while certain other
residues that differ from the original germline sequence are
maintained or are mutated to the corresponding residue of a
different germline sequence. Once obtained, antibodies and
antigen-binding fragments that contain one or more germline
mutations can be easily tested for one or more desired property
such as, improved binding specificity, increased binding affinity,
improved or enhanced antagonistic or agonistic biological
properties (as the case may be), reduced immunogenicity, etc.
Antibodies and antigen-binding fragments obtained in this general
manner are encompassed within the present invention.
[0050] The present invention also includes anti-ASIC1 antibodies
comprising variants of any of the HCVR, LCVR, and/or CDR amino acid
sequences disclosed herein having one or more conservative
substitutions. For example, the present invention includes
anti-ASIC1 antibodies having HCVR, LCVR, and/or CDR amino acid
sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or
fewer, etc. conservative amino acid substitutions relative to any
of the HCVR, LCVR, and/or CDR amino acid sequences disclosed
herein.
[0051] The term "epitope" refers to an antigenic determinant that
interacts with a specific antigen binding site in the variable
region of an antibody molecule known as a paratope. A single
antigen may have more than one epitope. Thus, different antibodies
may bind to different areas on an antigen and may have different
biological effects. Epitopes may be either conformational or
linear. A conformational epitope is produced by spatially
juxtaposed amino acids from different segments of the linear
polypeptide chain. A linear epitope is one produced by adjacent
amino acid residues in a polypeptide chain. In certain
circumstance, an epitope may include moieties of saccharides,
phosphoryl groups, or sulfonyl groups on the antigen.
[0052] The term "substantial identity" or "substantially
identical," when referring to a nucleic acid or fragment thereof,
indicates that, when optimally aligned with appropriate nucleotide
insertions or deletions with another nucleic acid (or its
complementary strand), there is nucleotide sequence identity in at
least about 95%, and more preferably at least about 96%, 97%, 98%
or 99% of the nucleotide bases, as measured by any well-known
algorithm of sequence identity, such as FASTA, BLAST or Gap, as
discussed below. A nucleic acid molecule having substantial
identity to a reference nucleic acid molecule may, in certain
instances, encode a polypeptide having the same or substantially
similar amino acid sequence as the polypeptide encoded by the
reference nucleic acid molecule.
[0053] As applied to polypeptides, the term "substantial
similarity" or "substantially similar" means that two peptide
sequences, when optimally aligned, such as by the programs GAP or
BESTFIT using default gap weights, share at least 95% sequence
identity, even more preferably at least 98% or 99% sequence
identity. Preferably, residue positions which are not identical
differ by conservative amino acid substitutions. A "conservative
amino acid substitution" is one in which an amino acid residue is
substituted by another amino acid residue having a side chain (R
group) with similar chemical properties (e.g., charge or
hydrophobicity). In general, a conservative amino acid substitution
will not substantially change the functional properties of a
protein. In cases where two or more amino acid sequences differ
from each other by conservative substitutions, the percent sequence
identity or degree of similarity may be adjusted upwards to correct
for the conservative nature of the substitution. Means for making
this adjustment are well-known to those of skill in the art. See,
e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331, herein
incorporated by reference. Examples of groups of amino acids that
have side chains with similar chemical properties include (1)
aliphatic side chains: glycine, alanine, valine, leucine and
isoleucine; (2) aliphatic-hydroxyl side chains: serine and
threonine; (3) amide-containing side chains: asparagine and
glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and
tryptophan; (5) basic side chains: lysine, arginine, and histidine;
(6) acidic side chains: aspartate and glutamate, and (7)
sulfur-containing side chains are cysteine and methionine.
Preferred conservative amino acids substitution groups are:
valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine,
alanine-valine, glutamate-aspartate, and asparagine-glutamine.
Alternatively, a conservative replacement is any change having a
positive value in the PAM250 log-likelihood matrix disclosed in
Gonnet et al. (1992) Science 256: 1443-1445, herein incorporated by
reference. A "moderately conservative" replacement is any change
having a nonnegative value in the PAM250 log-likelihood matrix.
[0054] Sequence similarity for polypeptides, which is also referred
to as sequence identity, is typically measured using sequence
analysis software. Protein analysis software matches similar
sequences using measures of similarity assigned to various
substitutions, deletions and other modifications, including
conservative amino acid substitutions. For instance, GCG software
contains programs such as Gap and Bestfit which can be used with
default parameters to determine sequence homology or sequence
identity between closely related polypeptides, such as homologous
polypeptides from different species of organisms or between a wild
type protein and a mutein thereof. See, e.g., GCG Version 6.1.
Polypeptide sequences also can be compared using FASTA using
default or recommended parameters, a program in GCG Version 6.1.
FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent
sequence identity of the regions of the best overlap between the
query and search sequences (Pearson (2000) supra). Another
preferred algorithm when comparing a sequence of the invention to a
database containing a large number of sequences from different
organisms is the computer program BLAST, especially BLASTP or
TBLASTN, using default parameters. See, e.g., Altschul et al.
(1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic
Acids Res. 25:3389-402, each herein incorporated by reference.
Biological Characteristics of the Antibodies
[0055] The present invention includes antibodies that specifically
bind cell surface expressed ASIC1. As used herein, an antibody
specifically binds cell surface expressed ASIC1 if the antibody
shows detectable binding to a cell that naturally or artificially
expresses ASIC1 but does not show detectable binding to an
equivalent cell that does not express ASIC1. One exemplary assay
format that can be used to determine whether an antibody
specifically binds cell surface-expressed ASIC1 is fluorescence
activated cell sorting (FACS), as illustrated in Example 3 herein.
Qualitative positive FACS binding of an antibody to cells which
express ASIC1, as shown in Table 2, can be used to identify an
antibody as specifically binding cell surface-expressed ASIC1. FACS
can also be used to quantitatively assess antibody binding to cell
which express ASIC1 in terms of an EC.sub.50 value, as shown in
Example 3, Table 3. Thus, according to certain embodiments of the
present invention, an antibody "specifically binds cell
surface-expressed ASIC1" if the antibody, when tested in the FACS
assay format of Example 3 or a substantially similar assay format,
exhibits an EC.sub.50 value of about 5 nM or less (e.g., about 5.0
nM, 4.5 nM, 4.0 nM, 3.5 nM, 3.0 nM, 2.5 nM, 2.0 nM, 1.5 nM, 1.4 nM,
1.3 nM, 1.2 nM, 1.1 nM, 1.0 nM, 900 pM, 800 pM, 700 pM, 600 pM, 500
pM, 400 pM, 300 pM, 200 pM, 100 pM, 90 pM, 85 pM, 80 pM, 75 pM, 70
pM, or less).
[0056] The antibodies of the present invention, according to
certain embodiments, may also (or alternatively) function to
inhibit acid-induced, ASIC1-mediated ion currents in cells
expressing human ASIC1. As used herein, the expression "inhibits
acid-induced, ASIC1-mediated ion currents" means that, in an assay
in which acid-induced cellular ion currents or flux can be detected
and/or quantified, the addition of an antibody of the invention
detectably reduces or inhibits the acid-induced ion currents as
compared to the ion currents observed in the absence of the
antibody (e.g., in the presence of a non-specific negative control
antibody). A non-limiting exemplary assay that can be used to
determine if an antibody "inhibits acid-induced, ASIC1-mediated ion
currents" is illustrated in Example 4 herein. In this Example, low
pH-activated calcium flux is measured in ASIC1-expressing cells in
the presence of anti-ASIC1 antibodies ("FLIPR assay"). By varying
the amount of antibody used in this assay format, the amount of
antibody required to block 50% of low pH-induced ion flux can be
calculated and expressed as an IC.sub.50 value (see, e.g., Example
4, Table 5). The present invention includes anti-ASIC1 antibodies
that inhibit acid-induced, ASIC1-mediated ion currents with an
IC.sub.50 of less than about 10 nM when tested in a FLIPR assay at
pH of about 5.0 to about 6.0 (e.g., at pH 5.0, 5.1, 5.2, 5.3, 5.4,
5.5, 5.6, 5.7, 5.8, 5.9, or 6.0) as described above, or a
substantially similar assay. For example, the invention includes
anti-ASIC1 antibodies that exhibit an IC.sub.50 of less than about
9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8
nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, or
less, when tested in a FLIPR assay at pH 5.5 as described above, or
a substantially similar assay.
[0057] Other exemplary assay formats that can be used to determine
whether an antibody "inhibits acid-induced, ASIC1-mediated ion
currents" are illustrated in Examples 5 and 6 herein. In these
Examples, automated voltage-clamp, patch-clamp assays are used to
measure and/or assess the inhibition of current flux in cells that
express ASIC1 at acidic pH in the presence of an anti-ASIC1
antibody, as compared to the current flux observed under equivalent
circumstances in the absence of the antibody (e.g., in the presence
of a non-specific negative control antibody). An antibody is deemed
to "inhibit acid-induced, ASIC1-mediated ion currents" if the
antibody, when tested in a voltage-clamp, patch-clamp assay at an
antibody concentration of about 1 nM to about 100 nM, at a pH of
about 5.0 to about 6.0 (e.g., at pH 5.0, 5.1, 5.2, 5.3, 5.4, 5.5,
5.6, 5.7, 5.8, 5.9, or 6.0), causes at least a 10% current
inhibition (e.g., at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%,
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or greater
inhibition of current flux; see, e.g., Example 5, Table 6). In some
instances, the antibodies of the invention completely inhibit
current flux (100% inhibition) at 10 nM or higher (e.g., 100 nM),
when tested in a patch-clamp assay format as described above, or a
substantially similar assay.
[0058] The present invention also includes antibodies that inhibit
or reduce pain response(s) in various animal pain models. Exemplary
animal pain models useful for characterizing the anti-ASIC1
antibodies of the present invention are illustrated in Examples
7-9, herein. For example, the present invention includes anti-ASIC1
antibodies that attenuate or inhibit pain responses to acid-induced
visceral pain in a mouse model. (see, e.g., Example 7). In
particular, the present invention includes anti-ASIC1 antibodies
that exhibit at least a 20% inhibition of visceral pain responses
(e.g., abdominal constrictions in response to an intraperitoneal
injection of 0.6% acetic acid) when administered at a dose of about
1 or 10 mg/kg to a mouse model as shown in Example 7, or a
substantially similar model. In certain instances, the percent
inhibition in pain responses due to the administration of an
antibody of the present invention can be as high as about 30%, 35%,
40%, 45%, 50%, or higher when tested in the mouse animal pain model
of Example 7, or a substantially similar model. Other animal pain
models that can be used to characterize the anti-ASIC antibodies of
the present invention include, e.g., the mechanical nociception
pain response models of Example 8, the muscle pain models of
Example 9, and other similar animal models available in the art.
Thus, the present invention includes anti-ASIC1 antibodies capable
of attenuating or inhibiting pain responses to noxious mechanical
stimuli (see, e.g., Example 8); and/or acidic-saline- or
carrageenan-induced muscle hyperalgesia (see, e.g., Example 9), as
demonstrated in appropriate animal models as exemplified
herein.
Epitope Mapping and Related Technologies
[0059] The present invention includes anti-ASIC1 antibodies which
interact with one or more amino acids found within the
extracellular domain of human ASIC1 (amino acids 63 to 424 of SEQ
ID NO:401). The epitope to which the antibodies bind may consist of
a single contiguous sequence of 3 or more (e.g., 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) amino acids
located within the extracellular domain of ASIC1. Alternatively,
the epitope may consist of a plurality of non-contiguous amino
acids (or amino acid sequences) located within the extracellular
domain of ASIC1.
[0060] Various techniques known to persons of ordinary skill in the
art can be used to determine whether an antibody "interacts with
one or more amino acids" within a polypeptide or protein. Exemplary
techniques include, e.g., routine cross-blocking assay such as that
described Antibodies, Harlow and Lane (Cold Spring Harbor Press,
Cold Spring Harb., N.Y.), alanine scanning mutational analysis,
peptide blots analysis (Reineke, 2004, Methods Mol Biol
248:443-463), and peptide cleavage analysis. In addition, methods
such as epitope excision, epitope extraction and chemical
modification of antigens can be employed (Tomer, 2000, Protein
Science 9:487-496). Another method that can be used to identify the
amino acids within a polypeptide with which an antibody interacts
is hydrogen/deuterium exchange detected by mass spectrometry. In
general terms, the hydrogen/deuterium exchange method involves
deuterium-labeling the protein of interest, followed by binding the
antibody to the deuterium-labeled protein. Next, the
protein/antibody complex is transferred to water to allow
hydrogen-deuterium exchange to occur at all residues except for the
residues protected by the antibody (which remain
deuterium-labeled). After dissociation of the antibody, the target
protein is subjected to protease cleavage and mass spectrometry
analysis, thereby revealing the deuterium-labeled residues which
correspond to the specific amino acids with which the antibody
interacts. See, e.g., Ehring (1999) Analytical Biochemistry
267(2):252-259; Engen and Smith (2001) Anal. Chem.
73:256A-265A.
[0061] The present invention further includes anti-ASIC1 antibodies
that bind to the same epitope as any of the specific exemplary
antibodies described herein (e.g. H1M6712N, H1M6716N, H1M6718N,
H1M7101N, H2M7103N, H3M6713N, H3M6715N, H3M6720N, H3M6721N,
H3M6721N2, H3M6726N, H3M6760N, H3M7102N, H3M7118N, H4H6362P,
H4H6363P, H4H6364P, H4H6366P, H4H6372P, H4H6374P, H4H6375P,
H4H6379P, H4H6380P, H4H6381P, H4H6383P etc.). Likewise, the present
invention also includes anti-ASIC1 antibodies that compete for
binding to ASIC1 or to cell surface-expressed ASIC1 with any of the
specific exemplary antibodies described herein (e.g. H1M6712N,
H1M6716N, H1M6718N, H1M7101N, H2M7103N, H3M6713N, H3M6715N,
H3M6720N, H3M6721N, H3M6721N2, H3M6726N, H3M6760N, H3M7102N,
H3M7118N, H4H6362P, H4H6363P, H4H6364P, H4H6366P, H4H6372P,
H4H6374P, H4H6375P, H4H6379P, H4H6380P, H4H6381P, H4H6383P
etc.).
[0062] One can easily determine whether an antibody binds to the
same epitope as, or competes for binding with, a reference
anti-ASIC1 antibody by using routine methods known in the art. For
example, to determine if a test antibody binds to the same epitope
as a reference anti-ASIC1 antibody of the invention, the reference
antibody is allowed to bind to an ASIC1 protein (e.g., cell
surface-expressed ASIC1). Next, the ability of a test antibody to
bind to the ASIC1 molecule is assessed. If the test antibody is
able to bind to ASIC1 following saturation binding with the
reference anti-ASIC1 antibody, it can be concluded that the test
antibody binds to a different epitope than the reference anti-ASIC1
antibody. On the other hand, if the test antibody is not able to
bind to the ASIC1 molecule following saturation binding with the
reference anti-ASIC1 antibody, then the test antibody may bind to
the same epitope as the epitope bound by the reference anti-ASIC1
antibody of the invention. Additional routine experimentation
(e.g., peptide mutation and binding analyses) can then be carried
out to confirm whether the observed lack of binding of the test
antibody is in fact due to binding to the same epitope as the
reference antibody or if steric blocking (or another phenomenon) is
responsible for the lack of observed binding. Experiments of this
sort can be performed using ELISA, RIA, Biacore, flow cytometry or
any other quantitative or qualitative antibody-binding assay
available in the art. In accordance with certain embodiments of the
present invention, two antibodies bind to the same (or overlapping)
epitope if, e.g., a 1-, 5-, 10-, 20- or 100-fold excess of one
antibody inhibits binding of the other by at least 50% but
preferably 75%, 90% or even 99% as measured in a competitive
binding assay (see, e.g., Junghans et al., Cancer Res.
1990:50:1495-1502). Alternatively, two antibodies are deemed to
bind to the same epitope if essentially all amino acid mutations in
the antigen that reduce or eliminate binding of one antibody reduce
or eliminate binding of the other. Two antibodies are deemed to
have "overlapping epitopes" if only a subset of the amino acid
mutations that reduce or eliminate binding of one antibody reduce
or eliminate binding of the other.
[0063] To determine if an antibody competes for binding with a
reference anti-ASIC1 antibody, the above-described binding
methodology is performed in two orientations: In a first
orientation, the reference antibody is allowed to bind to an ASIC1
molecule (e.g., cell surface-expressed ASIC1) under saturating
conditions followed by assessment of binding of the test antibody
to the ASIC1 molecule. In a second orientation, the test antibody
is allowed to bind to an ASIC1 molecule under saturating conditions
followed by assessment of binding of the reference antibody to the
ASIC1 molecule. If, in both orientations, only the first
(saturating) antibody is capable of binding to the ASIC1 molecule,
then it is concluded that the test antibody and the reference
antibody compete for binding to ASIC1. As will be appreciated by a
person of ordinary skill in the art, an antibody that competes for
binding with a reference antibody may not necessarily bind to the
same epitope as the reference antibody, but may sterically block
binding of the reference antibody by binding an overlapping or
adjacent epitope.
Preparation of Human Antibodies
[0064] Methods for generating monoclonal antibodies, including
fully human monoclonal antibodies are known in the art. Any such
known methods can be used in the context of the present invention
to make human antibodies that specifically bind to human ASIC1.
[0065] Using VELOCIMMUNE.TM. technology or any other known method
for generating monoclonal antibodies, high affinity chimeric
antibodies to ASIC1 are initially isolated having a human variable
region and a mouse constant region. As in the experimental section
below, the antibodies are characterized and selected for desirable
characteristics, including affinity, selectivity, epitope, etc. The
mouse constant regions are replaced with a desired human constant
region to generate the fully human antibody of the invention, for
example wild-type or modified IgG1 or IgG4. While the constant
region selected may vary according to specific use, high affinity
antigen-binding and target specificity characteristics reside in
the variable region.
Bioequivalents
[0066] The anti-ASIC1 antibodies and antibody fragments of the
present invention encompass proteins having amino acid sequences
that vary from those of the described antibodies but that retain
the ability to bind human ASIC1. Such variant antibodies and
antibody fragments comprise one or more additions, deletions, or
substitutions of amino acids when compared to parent sequence, but
exhibit biological activity that is essentially equivalent to that
of the described antibodies. Likewise, the anti-ASIC1
antibody-encoding DNA sequences of the present invention encompass
sequences that comprise one or more additions, deletions, or
substitutions of nucleotides when compared to the disclosed
sequence, but that encode an anti-ASIC1 antibody or antibody
fragment that is essentially bioequivalent to an anti-ASIC1
antibody or antibody fragment of the invention. Examples of such
variant amino acid and DNA sequences are discussed above.
[0067] Two antigen-binding proteins, or antibodies, are considered
bioequivalent if, for example, they are pharmaceutical equivalents
or pharmaceutical alternatives whose rate and extent of absorption
do not show a significant difference when administered at the same
molar dose under similar experimental conditions, either single
does or multiple dose. Some antibodies will be considered
equivalents or pharmaceutical alternatives if they are equivalent
in the extent of their absorption but not in their rate of
absorption and yet may be considered bioequivalent because such
differences in the rate of absorption are intentional and are
reflected in the labeling, are not essential to the attainment of
effective body drug concentrations on, e.g., chronic use, and are
considered medically insignificant for the particular drug product
studied.
[0068] In one embodiment, two antigen-binding proteins are
bioequivalent if there are no clinically meaningful differences in
their safety, purity, and potency.
[0069] In one embodiment, two antigen-binding proteins are
bioequivalent if a patient can be switched one or more times
between the reference product and the biological product without an
expected increase in the risk of adverse effects, including a
clinically significant change in immunogenicity, or diminished
effectiveness, as compared to continued therapy without such
switching.
[0070] In one embodiment, two antigen-binding proteins are
bioequivalent if they both act by a common mechanism or mechanisms
of action for the condition or conditions of use, to the extent
that such mechanisms are known.
[0071] Bioequivalence may be demonstrated by in vivo and in vitro
methods. Bioequivalence measures include, e.g., (a) an in vivo test
in humans or other mammals, in which the concentration of the
antibody or its metabolites is measured in blood, plasma, serum, or
other biological fluid as a function of time; (b) an in vitro test
that has been correlated with and is reasonably predictive of human
in vivo bioavailability data; (c) an in vivo test in humans or
other mammals in which the appropriate acute pharmacological effect
of the antibody (or its target) is measured as a function of time;
and (d) in a well-controlled clinical trial that establishes
safety, efficacy, or bioavailability or bioequivalence of an
antibody.
[0072] Bioequivalent variants of anti-ASIC1 antibodies of the
invention may be constructed by, for example, making various
substitutions of residues or sequences or deleting terminal or
internal residues or sequences not needed for biological activity.
For example, cysteine residues not essential for biological
activity can be deleted or replaced with other amino acids to
prevent formation of unnecessary or incorrect intramolecular
disulfide bridges upon renaturation. In other contexts,
bioequivalent antibodies may include anti-ASIC1 antibody variants
comprising amino acid changes which modify the glycosylation
characteristics of the antibodies, e.g., mutations which eliminate
or remove glycosylation.
Species Selectivity and Species Cross-Reactivity
[0073] According to certain embodiments of the invention, the
anti-ASIC1 antibodies bind to human ASIC1 but not to ASIC1 from
other species. The present invention also includes anti-ASIC1
antibodies that bind to human ASIC1 and to ASIC1 from one or more
non-human species. For example, the anti-ASIC1 antibodies of the
invention may bind to human ASIC1 and may bind or not bind, as the
case may be, to one or more of mouse, rat, guinea pig, hamster,
gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel,
cynomolgus, marmoset, rhesus or chimpanzee ASIC1. The present
invention also includes anti-ASIC1 antibodies that selectively
block acid-induced ion currents through human ASIC1 channels (but
not through non-human ASIC1 channels).
[0074] Alternatively, according to certain embodiments, anti-ASIC1
antibodies are provided that block acid-induced ion currents
through human ASIC1 channels as well as through non-human (e.g.,
mouse, rat, etc.) ASIC1 channels (See, e.g., Example 5,
herein).
Immunoconjugates
[0075] The invention encompasses anti-ASIC1 monoclonal antibodies
conjugated to a therapeutic moiety ("immunoconjugate"), such as a
cytotoxin, a chemotherapeutic drug, an immunosuppressant or a
radioisotope. Cytotoxic agents include any agent that is
detrimental to cells. Examples of suitable cytotoxic agents and
chemotherapeutic agents for forming immunoconjugates are known in
the art, (see for example, WO 05/103081).
Multispecific Antibodies
[0076] The antibodies of the present invention may be monospecific,
bi-specific, or multispecific. Multispecific antibodies may be
specific for different epitopes of one target polypeptide or may
contain antigen-binding domains specific for more than one target
polypeptide. See, e.g., Tutt et al., 1991, J. Immunol. 147:60-69;
Kufer et al., 2004, Trends Biotechnol. 22:238-244. The anti-ASIC1
antibodies of the present invention can be linked to or
co-expressed with another functional molecule, e.g., another
peptide or protein. For example, an antibody or fragment thereof
can be functionally linked (e.g., by chemical coupling, genetic
fusion, noncovalent association or otherwise) to one or more other
molecular entities, such as another antibody or antibody fragment
to produce a bi-specific or a multispecific antibody with a second
binding specificity. For example, the present invention includes
bi-specific antibodies wherein one arm of an immunoglobulin is
specific for human ASIC1 or a fragment thereof, and the other arm
of the immunoglobulin is specific for a second therapeutic target
or is conjugated to a therapeutic moiety.
[0077] An exemplary bi-specific antibody format that can be used in
the context of the present invention involves the use of a first
immunoglobulin (Ig) C.sub.H3 domain and a second Ig C.sub.H3
domain, wherein the first and second Ig C.sub.H3 domains differ
from one another by at least one amino acid, and wherein at least
one amino acid difference reduces binding of the bispecific
antibody to Protein A as compared to a bi-specific antibody lacking
the amino acid difference. In one embodiment, the first Ig C.sub.H3
domain binds Protein A and the second Ig C.sub.H3 domain contains a
mutation that reduces or abolishes Protein A binding such as an
H95R modification (by IMGT exon numbering; H435R by EU numbering).
The second C.sub.H3 may further comprise a Y96F modification (by
IMGT; Y436F by EU). Further modifications that may be found within
the second C.sub.H3 include: D16E, L18M, N44S, K52N, V57M, and V82I
(by IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU) in
the case of IgG1 antibodies; N44S, K52N, and V82I (IMGT; N384S,
K392N, and V422I by EU) in the case of IgG2 antibodies; and Q15R,
N44S, K52N, V57M, R69K, E79Q, and V82I (by IMGT; Q355R, N384S,
K392N, V397M, R409K, E419Q, and V422I by EU) in the case of IgG4
antibodies. Variations on the bi-specific antibody format described
above are contemplated within the scope of the present
invention.
Therapeutic Formulation and Administration
[0078] The invention provides pharmaceutical compositions
comprising the anti-ASIC1 antibodies or antigen-binding fragments
thereof of the present invention. The pharmaceutical compositions
of the invention are formulated with suitable carriers, excipients,
and other agents that provide improved transfer, delivery,
tolerance, and the like. A multitude of appropriate formulations
can be found in the formulary known to all pharmaceutical chemists:
Remington's Pharmaceutical Sciences, Mack Publishing Company,
Easton, Pa. These formulations include, for example, powders,
pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or
anionic) containing vesicles (such as LIPOFECTINTm, Life
Technologies, Carlsbad, Calif.), DNA conjugates, anhydrous
absorption pastes, oil-in-water and water-in-oil emulsions,
emulsions carbowax (polyethylene glycols of various molecular
weights), semi-solid gels, and semi-solid mixtures containing
carbowax. See also Powell et al. "Compendium of excipients for
parenteral formulations" PDA (1998) J Pharm Sci Technol
52:238-311.
[0079] The dose of antibody administered to a patient may vary
depending upon the age and the size of the patient, target disease,
conditions, route of administration, and the like. The preferred
dose is typically calculated according to body weight or body
surface area. When an antibody of the present invention is used for
treating a condition or disease associated with ASIC1 activity in
an adult patient, it may be advantageous to intravenously
administer the antibody of the present invention normally at a
single dose of about 0.01 to about 20 mg/kg body weight, more
preferably about 0.02 to about 7, about 0.03 to about 5, or about
0.05 to about 3 mg/kg body weight. Depending on the severity of the
condition, the frequency and the duration of the treatment can be
adjusted. Effective dosages and schedules for administering
anti-ASIC1 antibodies may be determined empirically; for example,
patient progress can be monitored by periodic assessment, and the
dose adjusted accordingly. Moreover, interspecies scaling of
dosages can be performed using well-known methods in the art (e.g.,
Mordenti et al., 1991, Pharmaceut. Res. 8:1351).
[0080] Various delivery systems are known and can be used to
administer the pharmaceutical composition of the invention, e.g.,
encapsulation in liposomes, microparticles, microcapsules,
recombinant cells capable of expressing the mutant viruses,
receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol.
Chem. 262:4429-4432). Methods of introduction include, but are not
limited to, intradermal, intramuscular, intraperitoneal,
intravenous, subcutaneous, intranasal, epidural, and oral routes.
The composition may be administered by any convenient route, for
example by infusion or bolus injection, by absorption through
epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and
intestinal mucosa, etc.) and may be administered together with
other biologically active agents. Administration can be systemic or
local.
[0081] A pharmaceutical composition of the present invention can be
delivered subcutaneously or intravenously with a standard needle
and syringe. In addition, with respect to subcutaneous delivery, a
pen delivery device readily has applications in delivering a
pharmaceutical composition of the present invention. Such a pen
delivery device can be reusable or disposable. A reusable pen
delivery device generally utilizes a replaceable cartridge that
contains a pharmaceutical composition. Once all of the
pharmaceutical composition within the cartridge has been
administered and the cartridge is empty, the empty cartridge can
readily be discarded and replaced with a new cartridge that
contains the pharmaceutical composition. The pen delivery device
can then be reused. In a disposable pen delivery device, there is
no replaceable cartridge. Rather, the disposable pen delivery
device comes prefilled with the pharmaceutical composition held in
a reservoir within the device. Once the reservoir is emptied of the
pharmaceutical composition, the entire device is discarded.
[0082] Numerous reusable pen and autoinjector delivery devices have
applications in the subcutaneous delivery of a pharmaceutical
composition of the present invention. Examples include, but are not
limited to AUTOPEN.TM. (Owen Mumford, Inc., Woodstock, UK),
DISETRONIC.TM. pen (Disetronic Medical Systems, Bergdorf,
Switzerland), HUMALOG MIX 75/25.TM. pen, HUMALOG.TM. pen, HUMALIN
70/30.TM. pen (Eli Lilly and Co., Indianapolis, Ind.), NOVOPEN.TM.
I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN
JUNIOR.TM. (Novo Nordisk, Copenhagen, Denmark), BD.TM. pen (Becton
Dickinson, Franklin Lakes, N.J.), OPTIPEN.TM., OPTIPEN PRO.TM.,
OPTIPEN STARLET.TM., and OPTICLIK.TM. (Sanofi-Aventis, Frankfurt,
Germany), to name only a few. Examples of disposable pen delivery
devices having applications in subcutaneous delivery of a
pharmaceutical composition of the present invention include, but
are not limited to the SOLOSTAR.TM. pen (Sanofi-Aventis), the
FLEXPEN.TM. (Novo Nordisk), and the KWIKPEN.TM. (Eli Lilly), the
SURECLICK.TM. Autoinjector (Amgen, Thousand Oaks, Calif.), the
PENLET.TM. (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.
P.), and the HUMIRA.TM. Pen (Abbott Labs, Abbott Park Ill.), to
name only a few.
[0083] In certain situations, the pharmaceutical composition can be
delivered in a controlled release system. In one embodiment, a pump
may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref.
Biomed. Eng. 14:201). In another embodiment, polymeric materials
can be used; see, Medical Applications of Controlled Release,
Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla. In yet
another embodiment, a controlled release system can be placed in
proximity of the composition's target, thus requiring only a
fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical
Applications of Controlled Release, supra, vol. 2, pp. 115-138).
Other controlled release systems are discussed in the review by
Langer, 1990, Science 249:1527-1533.
[0084] The injectable preparations may include dosage forms for
intravenous, subcutaneous, intracutaneous and intramuscular
injections, drip infusions, etc. These injectable preparations may
be prepared by methods publicly known. For example, the injectable
preparations may be prepared, e.g., by dissolving, suspending or
emulsifying the antibody or its salt described above in a sterile
aqueous medium or an oily medium conventionally used for
injections. As the aqueous medium for injections, there are, for
example, physiological saline, an isotonic solution containing
glucose and other auxiliary agents, etc., which may be used in
combination with an appropriate solubilizing agent such as an
alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol,
polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80,
HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor
oil)], etc. As the oily medium, there are employed, e.g., sesame
oil, soybean oil, etc., which may be used in combination with a
solubilizing agent such as benzyl benzoate, benzyl alcohol, etc.
The injection thus prepared is preferably filled in an appropriate
ampoule.
[0085] Advantageously, the pharmaceutical compositions for oral or
parenteral use described above are prepared into dosage forms in a
unit dose suited to fit a dose of the active ingredients. Such
dosage forms in a unit dose include, for example, tablets, pills,
capsules, injections (ampoules), suppositories, etc. The amount of
the aforesaid antibody contained is generally about 5 to about 500
mg per dosage form in a unit dose; especially in the form of
injection, it is preferred that the aforesaid antibody is contained
in about 5 to about 100 mg and in about 10 to about 250 mg for the
other dosage forms.
Therapeutic Uses of the Antibodies
[0086] The antibodies of the invention are useful, inter alia, for
the treatment, prevention and/or amelioration of any disease or
disorder associated with or mediated by ASIC1 activity or treatable
by blocking or attenuating acid-induced, ASIC1-mediated ion
currents in neuronal cells of an individual. Exemplary diseases and
disorders that can be treated with the anti-ASIC1 antibodies of the
present invention include pain conditions such as nociceptive pain
and visceral pain (e.g., pain from inflammatory bowel
disease/irritable bowel syndrome, interstitial cystitis,
pancreatitis, endometriosis, chronic pelvic pain syndrome, etc.),
as well as pain associated with inflammation (e.g., inflammatory
muscle pain), polymyositis, post-operative incision (e.g.,
post-surgical pain), neuropathy (e.g., diabetic neuropathy),
sciatica, post-herpetic neuralgia, myofascial pain syndromes (e.g.,
chronic myofascial pain), arthritis, sickle cell, enteric nerve
ischemia, claudication pain, bone fracture, burn, osteoporotic
fracture, gout, migraine headache, fibromyalgia, complex regional
pain syndrome, acute herpetic pain, etc. The antibodies of the
invention may also be used to treat, prevent and/or ameliorate
conditions such as, e.g., neurodegenerative diseases (e.g.,
demyelinating diseases such as multiple sclerosis, amyotrophic
lateral sclerosis, etc.), brain injury (e.g., stroke, traumatic
brain injury, brain acidosis), neurological disorders (e.g.,
seizures, seizure disorders), and psychiatric diseases (e.g.,
depression, anxiety disorders, post-traumatic stress disorder,
panic disorder, etc.).
[0087] The anti-ASIC1 antibodies of the present invention are also
useful for treating or preventing cancer-associated pain.
"Cancer-associated pain" includes, e.g., bone cancer pain,
including pain from cancer that has metastasized to bone (e.g.,
breast cancer, prostate cancer, lung cancer, sarcoma, kidney
cancer, multiple myeloma, etc.). "Cancer-associated pain" also
includes pain more generally associated with cancerous conditions
such as, e.g., renal cell carcinoma, pancreatic carcinoma, breast
cancer, head and neck cancer, prostate cancer, malignant gliomas,
osteosarcoma, colorectal cancer, gastric cancer, malignant
mesothelioma, multiple myeloma, ovarian cancer, small cell lung
cancer, non-small cell lung cancer, synovial sarcoma, thyroid
cancer, or melanoma. The anti-ASIC1 antibodies of the present
invention are also useful for treating or preventing pain caused by
or associated with cancer therapy or anti-cancer medical
treatments, e.g., chemotherapy-induced neuropathic pain such as
pain caused by or associated with treatment with paclitaxel
(Taxol.TM.), docetaxel (Taxotere.RTM.); nitrosourea,
cyclophosphamide, doxorubicin, epirubicin, 5-fluorouracil,
topotecan, irinotecan, carmustine, estramustine, and platinum-based
chemotherapeutic compounds, such as cisplatin, carboplatin, and
iproplatin.
Combination Therapies
[0088] The present invention includes therapeutic administration
regimens which comprise administering an anti-ASIC1 antibody of the
present invention in combination with at least one additional
therapeutically active component. Non-limiting examples of such
additional therapeutically active components include other ASIC
inhibitors such as, e.g., a second anti-ASIC1 antibody, an antibody
directed against a different ASIC component (e.g., anti-ASIC2
antibody, anti-ASIC3 antibody, anti-ASIC4 antibody, etc.), a
peptide ASIC inhibitor (e.g., psalmotoxin-1 [PcTx1], APETx2, etc.),
and/or a small molecule ASIC inhibitor (e.g., amiloride, A-317567,
etc.).
[0089] Other agents that may be beneficially administered in
combination with the anti-ASIC1 antibodies of the invention include
cytokine inhibitors (including small-molecule cytokine inhibitors
and antibodies that bind to cytokines such as IL-1, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-8, IL-9, IL-11, IL-12, IL-13, IL-17, IL-18, or
to their respective receptors), antivirals, antibiotics,
analgesics, corticosteroids and/or NSAIDs.
[0090] The additional therapeutically active component(s) may be
administered prior to, concurrent with, or after the administration
of an anti-ASIC1 antibody of the present invention; (for purposes
of the present disclosure, such administration regimens are
considered the administration of an anti-ASIC1 antibody "in
combination with" an additional therapeutically active
component).
Diagnostic Uses of the Antibodies
[0091] The anti-ASIC1 antibodies of the present invention may also
be used to detect and/or measure ASIC1, or ASIC1-expressing cells
in a sample, e.g., for diagnostic purposes. For example, an
anti-ASIC1 antibody, or fragment thereof, may be used to diagnose a
condition or disease characterized by aberrant expression (e.g.,
over-expression, under-expression, lack of expression, etc.) of
ASIC1. Exemplary diagnostic assays for ASIC1 may comprise, e.g.,
contacting a sample, obtained from a patient, with an anti-ASIC1
antibody of the invention, wherein the anti-ASIC1 antibody is
labeled with a detectable label or reporter molecule.
Alternatively, an unlabeled anti-ASIC1 antibody can be used in
diagnostic applications in combination with a secondary antibody
which is itself detectably labeled. The detectable label or
reporter molecule can be a radioisotope, such as .sup.3H, .sup.14C,
.sup.32P, .sup.35S, or .sup.125I; a fluorescent or chemiluminescent
moiety such as fluorescein isothiocyanate, or rhodamine; or an
enzyme such as alkaline phosphatase, beta-galactosidase,
horseradish peroxidase, or luciferase. Specific exemplary assays
that can be used to detect or measure ASIC1 in a sample include
enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA),
and fluorescence-activated cell sorting (FACS).
[0092] Samples that can be used in ASIC1 diagnostic assays
according to the present invention include any tissue or fluid
sample obtainable from a patient which contains detectable
quantities of ASIC1 protein, or fragments thereof, under normal or
pathological conditions. Generally, levels of ASIC1 in a particular
sample obtained from a healthy patient (e.g., a patient not
afflicted with a disease or condition associated with abnormal
ASIC1 levels or activity) will be measured to initially establish a
baseline, or standard, level of ASIC1. This baseline level of ASIC1
can then be compared against the levels of ASIC1 measured in
samples obtained from individuals suspected of having a ASIC1
related disease or condition.
Examples
[0093] The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
description of how to make and use the methods and compositions of
the invention, and are not intended to limit the scope of what the
inventors regard as their invention. Efforts have been made to
ensure accuracy with respect to numbers used (e.g., amounts,
temperature, etc.) but some experimental errors and deviations
should be accounted for. Unless indicated otherwise, parts are
parts by weight, molecular weight is average molecular weight,
temperature is in degrees Centigrade, and pressure is at or near
atmospheric.
Example 1
Generation of Human Antibodies to Human ASIC1
[0094] To generate anti-human ASIC1 antibodies, a DNA immunization
procedure was used in which a DNA plasmid encoding full-length
human ASIC1, together with a separate plasmid encoding adjuvant,
were injected intradermally into a VELOCIMMUNE.RTM. mouse
(Regeneron Pharmaceuticals, Inc., Tarrytown, N.Y.). The site of
injection was then electroporated to induce host cell transfection
of the plasmids. The VELOCIMMUNE.RTM. mice used for the
immunization comprise DNA encoding human Immunoglobulin heavy and
kappa light chain variable regions and lack the endogenous mouse
asic1a gene. The antibody immune response was monitored by a cell
binding assay using cells engineered to express human ASIC1. When a
desired immune response was achieved, splenocytes were harvested
and fused with mouse myeloma cells to preserve their viability and
form hybridoma cell lines. The hybridoma cell lines were screened
and selected to identify cell lines that produce ASIC1-specific
antibodies. Using this technique several anti-ASIC1 chimeric
antibodies (i.e., antibodies possessing human variable domains and
mouse constant domains) were obtained; exemplary antibodies
generated in this manner were designated as follows: H1M6712N,
H1M6716N, H1M6718N, H1M7101N, H2M7103N, H3M6713N, H3M6715N,
H3M6720N, H3M6721N, H3M6721N2, H3M6726N, H3M6760N, H3M7102N, and
H3M7118N.
[0095] Anti-ASIC1 antibodies were also isolated directly from
antigen-positive B cells without fusion to myeloma cells, as
described in US 200710280945A1. Using this method, several fully
human anti-ASIC1 antibodies (i.e., antibodies possessing human
variable domains and human constant domains) were obtained;
exemplary antibodies generated in this manner were designated as
follows: H4H6362P, H4H6363P, H4H6364P, H4H6366P, H4H6372P,
H4H6374P, H4H6375P, H4H6379P, H4H6380P, H4H6381P, and H4H6383P.
[0096] Certain biological properties of the exemplary anti-ASIC1
antibodies generated in accordance with the methods of this Example
are described in detail in the Examples set forth below.
Example 2
Heavy and Light Chain Variable Region Amino Acid Sequences
[0097] Table 1 sets forth the heavy and light chain variable region
amino acid sequence pairs of selected anti-ASIC1 antibodies and
their corresponding antibody identifiers.
TABLE-US-00001 TABLE 1 Antibody SEQ ID NOs: Designation HCVR HCDR1
HCDR2 HCDR3 LCVR LCDR1 LCDR2 LCDR3 6712N 2 4 6 8 10 12 14 16 6716N
18 20 22 24 26 28 30 32 6718N 34 36 38 40 42 44 46 48 7101N 50 52
54 56 58 60 62 64 7103N 66 68 70 72 74 76 78 80 6713N 82 84 86 88
90 92 94 96 6715N 98 100 102 104 106 108 110 112 6720N 114 116 118
120 122 124 126 128 6721N 130 132 134 136 138 140 142 144 6721N2
146 148 150 152 154 156 158 160 6726N 162 164 166 168 170 172 174
176 6760N 178 180 182 184 186 188 190 192 7102N 194 196 198 200 202
204 206 208 7118N 210 212 214 216 218 220 222 224 6362P 226 228 230
232 234 236 238 240 6363P 242 244 246 248 250 252 254 256 6364P 258
260 262 264 266 268 270 272 6366P 274 276 278 280 282 284 286 288
6372P 290 292 294 296 298 300 302 304 6374P 306 308 310 312 314 316
318 320 6375P 322 324 326 328 330 332 334 336 6379P 338 340 342 344
346 348 350 352 6380P 354 356 358 360 362 364 366 368 6381P 370 372
374 376 378 380 382 384 6383P 386 388 390 392 394 396 398 400
[0098] Antibodies are typically referred to herein according to the
following nomenclature: Fc prefix (e.g. "H4H", "H1M", "H2M"),
followed by a numerical identifier (e.g. "6712" or "6362" as shown
in Table 1), followed by a "P" or "N" suffix. Thus, according to
this nomenclature, an antibody may be referred to herein as, e.g.,
"H1M6712N" or "H4H6362P". The H4H, H1M, and H3M prefixes on the
antibody designations used herein indicate the particular Fc region
of the antibody. For example, an "H1M" antibody has a mouse IgG1
Fc, whereas an "H4H" antibody has a human IgG4 Fc. As will be
appreciated by a person of ordinary skill in the art, an H1M or H3M
antibody can be converted to an H4H antibody, and vice versa, but
in any event, the variable domains (including the CDRs)--which are
indicated by the numerical identifiers shown in Table 1--will
remain the same.
Example 3
Antibody Binding to Cells Expressing Full-Length Human or Mouse
ASIC1
[0099] To further characterize anti-ASIC1 antibodies, their ability
to bind either (a) a mouse fibroblast 3T3 cell line stably
transfected to overexpress full length human ASIC1 (3T3/hASIC1;
amino acids 1-528 of NCBI accession number NP.sub.--001086.2 [SEQ
ID NO:401]), (b) a 3T3 cell line stably transfected to over express
full length mouse ASIC1a (3T3/mASIC1a; amino acids 1-526 of NCBI
accession number NP.sub.--033727), or (c) a ND7 cell line (ECACC,
#92090903) that is a fusion cell line of mouse neuroblastoma and
rat dorsal root ganglia that endogenously expresses rat ASIC1, was
determined using flow cytometry (FACS). ND7 cells were
differentiated by replacing the culture media with low-serum media
(0.5% FBS) containing 1 mM dibutyryl-cAMP (Cat. No. sc-201567A,
Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.). FACS binding
was tested for some antibodies on both undifferentiated ND7 cells
and differentiated ND7 cells.
[0100] To perform the FACS binding experiments, adherent cells were
collected using 1 mM EDTA in PBS, then washed, and re-suspended in
cold PBS containing 5% FBS. For each binding experiment, each
anti-ASIC1 antibody (at final concentrations of 10 nM of purified
antibodies or 3.3 nM for antibody supernatants for binding to
3T3/hASIC1 cells and 5 nM for binding to 3T3/mASIC1a or ND7 cells)
was added to 250,000 cells in 500 .mu.L of PBS with 5% FBS. After
incubation for 20 minutes at room temperature, a secondary antibody
which recognizes human Fc (Cat. No. 109-136-098, Jackson
ImmunoResearch Laboratories, Inc., West Grove, Pa.) or mouse Fc
(Cat. No. 550826, BD Biosciences, San Jose, Calif.) and is
conjugated to allophycocyanin, was then added to the cell mixture
at a final concentration of 13.3 nM. After incubating for 20
minutes on ice, the cells were washed and resuspended in PBS
containing 5% FBS, then sorted and analyzed on a flow cytometer
(FACSCalibur, BD Biosciences, San Jose, Calif.) to determine
relative binding by the candidate antibodies to the tested cell
lines. Histograms of cells stained with anti-ASIC1 antibodies were
compared with those of cells stained with secondary antibody alone.
Percentage of ASIC1 signal over secondary antibody alone was
calculated using FlowJo software (Tree Star, Ashland, Oreg.). The
samples stained with anti-ASIC1 antibodies were recorded as FACS
positive when gated greater than 10%. The samples stained with
anti-ASIC1 antibodies were recorded as FACS negative when gated
lower than 1%. The samples stained with anti-ASIC1 antibody were
recorded as weak when gated between 1%-10%. The binding
specificities of the anti-ASIC1 antibodies to 3T3/hASIC1 cells,
3T3/mASIC1a cells and ND7 cells are summarized in Table 2 (ND=not
determined).
TABLE-US-00002 TABLE 2 Binding Specificity of Anti-ASIC1 Antibodies
As Determined by FACS FACS Binding to FACS Binding to FACS Binding
to FACS Binding to Undifferentiated Differentiated Antibody
3T3/hASIC1 3T3/mASIC1a ND7 cells ND7 cells H1M6712N Positive ND ND
ND H3M6721N Positive Positive Negative ND H1M6718N Positive
Positive Positive Positive H4H6372P Negative ND ND ND H4H6374P
Negative ND ND ND H4H6375P Negative ND ND ND H4H6379P Negative ND
ND ND H4H6380P Negative ND ND ND H4H6381P Negative ND ND ND
H4H6383P Negative ND ND ND H4H6362P Negative ND ND ND H4H6363P
Positive ND ND ND H4H6364P Positive ND ND ND H1M7101N Positive
Positive Positive ND H1M6716N Positive ND ND ND H3M6726N Positive
Positive Positive Positive H3M6720N Positive Negative Negative
Negative H3M6713N Positive ND ND ND H3M7102N Positive Positive
Positive ND H3M6760N Positive ND ND ND H2M7103N Positive Positive
Negative Negative H3M6715N Positive ND ND ND H3M7118N Positive Weak
Weak Positive H4H6366P Positive Positive Positive Positive
H4H6721N2 Positive Positive Positive Positive
[0101] Binding affinity of selected antibodies to 3T3/hASIC1 cells
was further examined by FACS using multiple antibody concentrations
(67 nM, 6.7 nM, 0.67 nM, 67 pM, and 6.7 pM) from which approximate
EC.sub.50 values were calculated. The mean fluorescence intensity
(MFI) signal observed for the anti-ASIC1 antibodies was subtracted
by the background signal (secondary antibody alone) and plotted as
a function of antibody concentration to determine EC.sub.50 values
using GraphPad Prism (Table 3).
TABLE-US-00003 TABLE 3 EC.sub.50 Values for Select Anti-ASIC1
Antibodies Binding to 3T3/hASIC1 Cells Antibody EC.sub.50 H1M6712N
<100 pM H3M6721N 85 pM H1M6718N 550 pM H4H6363P 836 pM H3M6713N
215 pM H3M6715N 72 pM H1M6716N 23 pM H3M6720N 1.1 nM H3M6726N 2.6
nM H3M6760N 853 pM H1M7101N 720 pM H3M7102N 5.4 nM H3M7118N >67
nM H2M7103N 1.7 nM H4H6364P 1.5 nM H4H6366P 1.0 nM H4H6721N2 1.7
nM
[0102] As shown in Table 2, seventeen of the 25 antibodies tested
demonstrated specific binding to 3T3/hASIC1 cell line; eight of 10
antibodies tested demonstrated positive binding to the 3T3/mASIC1a
cells; six of 10 antibodies tested demonstrated positive binding to
the undifferentiated ND7 cell line; and five of 7 antibodies tested
demonstrated positive binding to the differentiated ND7 cell line.
Notably, one antibody (H3M7118N) demonstrated weak binding to both
3T3/mASIC1a and undifferentiated ND7 cell lines but positive
binding to 3T3/hASIC1 cells. As shown in Table 3, the anti-ASIC1
antibodies tested at multiple antibody concentrations demonstrated
high affinity FACS binding with approximate EC.sub.50 values as low
as 23 pM for binding to the 3T3/hASIC1 cells.
Example 4
Anti-ASIC1 Antibodies Block Acid-Mediated Cell Signaling in a
Cellular Calcium Flux Assay
[0103] To characterize functional blocking of acid-mediated cell
signaling by anti-ASIC1 antibodies, an assay that measures cellular
calcium flux was implemented using a cell line, HEK293 CL:1F10
(1F10), that was transiently transfected to express human ASIC1
(amino acids 1-528 of NCBI accession number NP.sub.--0010862.2 [SEQ
ID NO:401]). This cell line was created from the parental line
HEK293/D9 that was stably transfected to express human Par2.
Transfected cells were incubated at 37.degree. C., 5% CO.sub.2 for
2 days before replating into a 96-well black, clear bottom assay
plate at a concentration of 100,000 cells per well. Cells were
allowed to adhere to the plate at room temperature for 20 minutes
then incubated overnight at 37.degree. C., 5% CO.sub.2.
[0104] The Fluo-4 NW calcium assay kit (Invitrogen, # F36206) was
used to determine the level of intracellular calcium flux within
cells activated by low pH buffers. Assay buffer was prepared
according to the manufacturer's specifications. Fifty .mu.L of
probenecid (77 .mu.g/.mu.L) was added to 5 mL of buffer C
(2.times.HBSS), which was then added to component A (Fluo-4 dye).
Anti-ASIC1 antibodies were diluted in the Fluo-4 dye to a
concentration of 250 nM for the single point blocking assay. The
antibodies that blocked calcium flux stimulated by low pH buffers
were further characterized in this assay using multiple antibody
concentrations. Anti-ASIC1 antibodies were diluted to a
concentration of 250 nM in the dye and an 8 point 1:3 dilution
series (ranging from 250 to 0.1 nM) was used to determine the
blocking IC.sub.50 of each antibody. The cell culture media was
removed from the assay plate containing cells and 504 of the Fluo-4
dye containing anti-ASIC1 antibody was then added. The plates were
incubated at 37.degree. C., 5% CO.sub.2 for 1 hour before reading
by FLIPR Tetra (Molecular Devices).
[0105] The pH of buffer C was adjusted to pH 5.0 or pH 5.5 and
added to a reservoir plate before addition to the cells. The FLIPR
Tetra then added 504 of the low pH buffer from the reservoir plate
to the cells in the assay plate at a speed of 50 .mu.L per second.
The calcium signal produced by each well for 10 seconds prior to
buffer addition (pre-read) and for 100 seconds after buffer
addition was measured by FLIPR Tetra using an excitation wavelength
setting of 470-490 nm and an emission wavelength setting of 515-575
nm. The difference between the maximum observed value obtained
after buffer addition and the minimum value during the entire assay
including both the pre-read and after buffer addition was
calculated and graphed using Graph Pad Prism. Results are shown in
Tables 4 and 5.
TABLE-US-00004 TABLE 4 Blocking of Acid-Mediated Cellular Calcium
Flux by 250 nM of Anti-ASIC1 Antibodies at pH 5.5 and 5.0 FLIPR 250
nM Single Point Antibody pH 5.5 pH 5.0 H1M6712N Weak Neg H3M6721N
Pos Pos H1M6718N Pos Pos H1M7101N Neg Neg H1M6716N Weak Weak
H3M6726N Neg Neg H3M6720N Neg Neg H3M6713N Weak Weak H3M7102N Neg
Neg H3M6760N Pos Weak H2M7103N Neg Neg H3M6715N Weak Weak H3M7118N
Neg Neg H4H6372P Weak Neg H4H6374P Weak Neg H4H6375P Weak Weak
H4H6379P Neg Neg H4H6380P Weak Neg H4H6381P Weak Neg H4H6383P Neg
Neg H4H6362P Neg Neg H4H6363P Neg Neg H4H6364P Neg Neg H4H6366P Neg
Neg
TABLE-US-00005 TABLE 5 Dose dependent blocking of acid-mediated
cellular calcium flux by anti-ASIC1 antibodies at pH 5.5 and 5.0
FLIPR Dose Curve Antibody pH 5.5% Block pH 5.5 IC.sub.50 nM pH 5.0%
Block pH 5.0 IC.sub.50 nM H1M6712N 64% 6 nM 10%, No dose dep. No
dose dep. H3M6721N 44% 0.3 nM 25% IC* H1M6718N 78% 0.6 nM 48% IC*
H3M6713N 63% 0.2 nM 23%, No dose dep. No dose dep. H3M6715N 39% 0.1
nM 10%, No dose dep. No dose dep. H1M6716N 37% 1.1 nM 25%, No dose
dep. No dose dep. H3M6760N 71% 0.9 nM 56% 1 nM H4H6375P 27% 0.1 nM
10%, No dose dep. No dose dep. H4H6380P Neg Neg Neg Neg H4H6381P
Neg Neg Neg Neg
[0106] As shown in Table 4, two of the 24 antibodies, H3M6721 N and
H1M6718N, exhibited greater than 30% blockade of the calcium flux
(Pos) at the single concentration of 250 nM at both pH 5.5 and pH
5.0, and one antibody (H3M6760N) exhibited greater than 30% block
at only pH 5.5. Twelve of the 24 antibodies at pH 5.5 and 17 of the
24 antibodies at pH 5.0 tested at the single concentration of 250
nM did not exhibit measurable blockade (Neg). Nine of the 24
antibodies at pH 5.5, and 5 of the 24 antibodies at pH 5.0, tested
at the single concentration of 250 nM exhibited a reduction in
calcium flux between 10-30% (Weak).
[0107] As shown in Table 5, eight of the 10 antibodies tested for
dose dependent blocking at pH 5.5 exhibited a percent blockade of
the calcium flux ranging from 27% to 78% and IC.sub.50 values
ranging from 0.1 nM to 6 nM. Two of the antibodies tested for dose
dependent calcium flux blockade at pH 5.5, H4H6380P and H4H6381P,
exhibited no measurable blockade. Two of the 10 antibodies tested
for dose dependent blocking at pH 5.0, H3M6721 N and H1M6718N,
exhibited a 25% and 48% blockade of the calcium flux, respectively,
but IC.sub.50 values could not be determined (10*) despite showing
dose dependence. One of the 10 antibodies tested for dose dependent
blocking at pH 5.0, H3M6760N, exhibited a 56% blockade of the
calcium flux and an IC.sub.50 value of 1 nM. Five of the 10
antibodies tested for dose dependent calcium flux blockade at pH
5.0 exhibited no dose dependent blockade but blocked between 10%
and 25% of the calcium flux at each of the antibody concentrations
tested. Two of the 10 antibodies tested for dose dependent blocking
at pH 5.0, H4H6380P and H4H6381P, exhibited no measurable
blockade.
Example 5
Anti-ASIC1 Antibodies Block Acid-Induced ASIC1 Ion Currents in an
Automated Voltage-Clamp Patch-Clamp Assay [Q-Patch]
[0108] The Q-Patch (Sophion Bioscience, Inc., Ballerup, Denmark), a
microchip-based automated patch-clamp system, was used to determine
the ability of the anti-ASIC1 antibodies to inhibit either the
human ASIC1 current in a stably transfected HEK293 cell line
expressing the full length human ASIC1 channel (HEK/hASIC1; amino
acids 1-528 of NCBI accession number NP.sub.--001086.2) or the
mouse ASIC1a current in a stably transfected 3T3 cell line
expressing the full-length mouse ASIC1a channel (3T3/mASIC1a; amino
acids 1-526 of NCBI accession number NP.sub.--033727).
[0109] HEK/hASIC1 cells were cultured in DMEM high glucose media,
10% fetal bovine serum (FBS), 1% non-essential amino acids and 500
.mu.g/mL Geneticin.RTM. (Invitrogen, #10131). 3T3/mASIC1a cells
were cultured in DMEM high glucose media, 10% FBS, 1%
penicillin/streptomycin/glutamine (Invitrogen, #10378-016), and 400
ug/mL Geneticin.RTM.. On the day of the recordings, cells were
harvested with Detachin cell detachment solution (Genlantis, San
Diego, Calif., # T100100), centrifuged and resuspended in 1.4 mL
serum free solution [CHO-SFM-II media (Invitrogen, #31033), HEPES
25 mM and penicillin/streptomycin 100 units/mL]. The cell
suspension was then incubated on a shaker for 40 minutes at room
temperature (RT). Two or three anti-ASIC1 antibodies and a control
antibody were run in parallel in one experiment. Thus, at the end
of the incubation, the cell suspension was dispensed into 4 tubes
(approximately 5.times.10.sup.5 cells in 300 .mu.L/tube) and the
antibodies were diluted to a final concentration of 100 nM directly
in the tubes for single point experiments, or at a range of
concentrations for dose response experiments and then incubated on
a shaker for 20 minutes at RT. At the end of the incubation, cells
were loaded on the Q-Patch.
[0110] Cells were first perfused with a buffer at pH 7.4 (NaCl 140
mM, KCl 4 mM, MgCl.sub.2 1 mM, CaCl.sub.2 2 mM, glucose 5 mM and
HEPES 10 mM) containing 0.2% (w/v) bovine serum albumin
(extracellular buffer) and the antibody of interest at a final
concentration of 100 nM for single point experiments, or at a range
of concentrations for dose response experiments, was added and
allowed to incubate for about 3 minutes. Then, the human ASIC1
current was elicited for one second by the addition of the
extracellular buffer adjusted to pH 6.0 while cells were maintained
at a holding potential of -80 mV. Thirty pM of amiloride was added
after each recording on the Q-Patch to demonstrate that the cells
were responsive through the duration of the assay. The composition
of the intracellular recording solution was CsCl 140 mM, MgCl.sub.2
4 mM, EGTA 10 mM and HEPES 10 mM; adjusted to pH 7.3 with CsOH.
[0111] All anti-ASIC1 antibodies were tested in quadruplicate in
parallel with the control irrelevant antibody. Channel blocking was
measured as percent inhibition of current flux in the presence of
anti-ASIC1 antibody relative to current flux in the presence of the
control irrelevant antibody, averaged over multiple blocking
experiments. Results are summarized in Table 6.
TABLE-US-00006 TABLE 6 Percent Inhibition of Acid-Induced Human
ASIC1 Currents by Anti-ASIC1 Antibodies at 100 nM Antibody Current
Number of concentration inhibition Antibody wells tested (nM) (%)
H1M6712N 10 100 0 H3M6715N 7 100 30 H3M6720N 7 100 82 H3M6726N 3
100 85 H3M6721N 14 100 100 H1M6718N 8 100 100 H4H6372P 4 100 0
H4H6374P 8 100 0 H4H6375P 5 100 0 H4H6379P 4 100 30 H4H6380P 5 100
0 H4H6381P 6 100 25 H4H6383P 4 100 15 H4H6362P 4 100 29 H4H6363P 4
100 0 H4H6364P 2 100 0 H4H6366P 8 100 72 H3M7099N 4 100 25 H1M7101N
4 100 97 H3M7102N 3 100 100 H2bM7103N 7 100 92 H3M7104N 7 100 35
H1M7117N 4 100 30
[0112] As shown in Table 6, seventeen of the 23 antibodies tested
at 100 nM on the Q-Patch demonstrated functional inhibition of
human ASIC1 current with 9 of the 17 antibodies showing a blockade
greater than 70%. Eleven antibodies (H1M6718N, H3M6720N, H3M6721 N,
H3M6726N, H4H6366P, H1M7101N, H3M7102N, H2bM7103N, H3M7118N,
H4H6718N, and H4H6721N2) were further tested for their ability to
inhibit the human ASIC1 current at different concentrations on the
Q-Patch, and nine antibodies (H4H6718N, H3M6720N, H3M6721N,
H1M7101N, H3M7102N, H2bM7103N, H3M6726N, H4H6366P, and H3M7118N)
were tested for their ability to inhibit the mouse ASIC1 current.
The percentage of blockade observed for these antibodies is
summarized in Table 7 (human ASIC1) and Table 8 (mouse ASIC1).
TABLE-US-00007 TABLE 7 Percent Inhibition of Acid-Induced Human
ASIC1 Currents by Anti-ASIC1 Antibodies at Various Antibody
Concentrations Antibody % Current Number of concentration
inhibition .+-. Antibody wells tested (nM) SEM H1M6718N 4 100 100
.+-. 0 18 10 99 .+-. 1 13 1 63 .+-. 13 8 0.1 0 .+-. 0 H3M6720N 13
100 83 .+-. 9 8 50 88 .+-. 6 3 10 70 4 1 0 H3M6721N 14 100 100 8 50
100 11 10 75 .+-. 10 6 1 30 H3M6726N 14 100 77 .+-. 3 12 10 30 .+-.
11 7 1 15 .+-. 15 H4H6366P 7 100 76 .+-. 6 6 10 53 .+-. 8 7 1 38
.+-. 15 H1M7101N 4 100 97 10 10 .sup. 99 .+-. 0.7 4 5 96 10 1 57
.+-. 18 4 0.1 7 H3M7102N 4 100 99 8 10 96 .+-. 1 3 5 35 10 1 0 .+-.
0 H2bM7103N 7 100 96 .+-. 3 3 50 96 5 10 61 .+-. 15 4 1 0 H3M7118N
2 100 99 2 10 89 2 1 30 H4H6718N 7 10 100 6 5 98 .+-. 2 3 1 97 8
0.6 66 .+-. 6 4 0.3 54 4 0.1 12 H4H6721N2 7 10 95 .+-. 2 13 5 93
.+-. 1 7 1 59 .+-. 10 8 0.6 32.7 .+-. 0.1 3 0.3 40 4 0.1 1
TABLE-US-00008 TABLE 8 Percent Inhibition of Acid-Induced Mouse
ASIC1a Currents by Anti-ASIC1 Antibodies at Various Antibody
Concentrations Antibody % Current Number of concentration
inhibition .+-. Antibody wells tested (nM) SEM H4H6718N 10 10 90 4
5 98 3 2 96 3 1 71 9 0.3 36 .+-. 3 2 0.1 20 H3M6720N 4 100 83 4 50
83 3 10 46 4 5 19 10 1 12 .+-. 3 6 0.1 21 .+-. 8 H3M6721N 4 100 91
3 10 57 4 1 0 H4H6721N2 8 25 99 .+-. 1 7 10 62 H1M7101N 4 100 90
H3M7102N 4 100 100 H2bM7103N 8 100 67 .+-. 2 3 50 77 3 10 30 2 5 32
10 1 33 .+-. 5 7 0.1 3 .+-. 1 H3M6726N 4 100 51 3 50 38 3 5 23 4 1
3 H4H6366P 1 100 46 4 10 30 3 5 28 4 1 10 H3M7118N 7 100 92 .+-. 3
3 50 87 8 10 36 .+-. 23 4 5 12 6 1 6 .+-. 6
[0113] As shown in Table 7, one antibody, H3M6726N, blocked the
human ASIC1 current with an apparent IC.sub.50 greater than 10 nM,
while six antibodies (H3M6720N, H3M6721 N, H4H6366P, H3M7102N,
H2bM7103N and H3M7118N) blocked the human ASIC1 current with an
apparent IC.sub.50 of 10 nM or less. Four of the antibodies,
H1M6718N, H1M7101N, H4H6718N, and H4H6721 N2, blocked the human
ASIC1 current with an apparent IC.sub.50 less than 1 nM.
[0114] As shown in Table 8, six of the 10 anti-ASIC1 antibodies
(H4H6718N, H3M6721 N, H4H6721 N2, H1M7101N, H3M7102N and H3M7118N)
tested on the mouse ASIC1 expressing cells inhibited 90 to 100% of
the mouse ASIC1 current at highest antibody concentration tested,
while four antibodies (H3M6720N, H3M6726N, H4H6366P, and H2bM7103N)
only inhibited the current by approximately 80% or less. H3M7118N,
H2bM7103N, H3M6720N and H3M6721 N blocked the mouse ASIC1 current
with an apparent IC.sub.50 less than 25 nM. H4H6718N blocked the
human ASIC1 current with an apparent IC.sub.50 less than 1 nM.
[0115] The Q-Patch was also used to determine the ability of the
anti-ASIC1 antibody H4H6718N to inhibit the ASIC1 current in the
ND7/23 cell line (ECACC, #92090903), which is a fusion cell line of
mouse neuroblastoma and rat dorsal root ganglia that endogenously
expresses rat ASIC1.
[0116] ND7/23 cells were cultured in DMEM high glucose media
containing 10% FBS, 2 mM glutamine, 1% penicillin-streptomycin
(Invitrogen, #10378-016). The day after seeding, ND7/23 cells were
differentiated by replacing the culture media with low-serum media
(0.5% FBS) containing 1 mM dibutyryl-cAMP (Santa Cruz, #
sc-201567A). On the day of the recordings, cells were harvested
using StemPro Accutase cell dissociation reagent (Invitrogen, #
A11105-01), centrifuged, and resuspended in 1 mL of extracellular
buffer solution. The cell suspension was then loaded on the
Q-Patch.
[0117] Cells were first perfused with an extracellular buffer
solution at pH 7.4 (NaCl 140 mM, KCl 4 mM, MgCl.sub.2 1 mM,
CaCl.sub.2 2 mM, glucose 5 mM and HEPES 10 mM, adjusted to pH 7.4
with NaOH) containing 0.2% (w/v) bovine serum albumin for 6 minutes
to stabilize the patch. The rat ASIC1 current was then elicited for
one second by the addition of the extracellular buffer, which was
adjusted to pH 6.0, while the cells were maintained at a holding
potential of -80 mV. The rat ASIC1 current was elicited 2 times in
extracellular buffer at pH 6 and then 2 additional times in the
same extracellular buffer containing either 10 nM of an isotype
control antibody or 10 nM of the anti-ASIC1 antibody (H4H6718N,
H3M6720N, H2bM7103N, H3M6726N, H4H6366P and H3M7118N). After the
anti-ASIC1 antibody recordings 10 nM of the selective ASIC1
antagonist PcTx1 (Alomone Labs, # STP-200) was added to the cells
to evaluate the contribution of ASIC1-specific currents to the
current elicited by extracellular buffer at pH 6. The composition
of the intracellular recording solution was CsF 120 mM, NaCl 15 mM,
EGTA 10 mM and HEPES 10 mM; adjusted to pH 7.3 with CsOH.
[0118] Channel blocking was measured as percent inhibition of
current flux in the presence of anti-ASIC1 antibody relative to the
current flux measured before the application of the antibody and
was compared to the percent inhibition of current flux in the
presence of PcTx1, which was used to define the maximum
ASIC1-specific current blockade. Results are shown in Table 9.
TABLE-US-00009 TABLE 9 Percent Inhibition of Acid-Induced Rat
ASIC1a Currents in ND7 Cells by Anti-ASIC1 Antibodies Antibody
Percent Current Number of Concentration Inhibition .+-. Antibody
Wells Tested (nM) SEM H4H6718N 9 10 100 H3M6720N 4 10 43 .+-. 15
H2b7103N 5 10 26 .+-. 14 H3M6726N 5 10 7 .+-. 6 H4H6366P 3 10 36
.+-. 20 H3M7118N 10 10 65 .+-. 11 Isotype Control 21 10 15 .+-.
3
[0119] As shown in Table 9, H4H6718N demonstrated a 100% inhibition
of the rat ASIC1 currents in differentiated ND7/23 cells at a
concentration of 10 nM (n=9) while H3M6720N and H3M7118N inhibited
the current by approximately 43% and 65%, respectively. Three
antibodies (H2bM7103N, H3M6726N and H4H6366P) did not demonstrate
significant inhibition of rat ASIC1 currents at 10 nM in these
experiments.
Example 6
An Anti-ASIC1 Antibody Blocks Acid-Induced ASIC1 Ion Currents in an
Automated Voltage-Clamp Patch-Clamp Assay [Port-A-Patch]
[0120] The Port-a-Patch (Nanion Technologies Inc., North Brunswick,
N.J.), a microchip-based automated patch-clamp system, was used to
determine the half maximal inhibitory concentration (IC.sub.50) of
the anti-ASIC1 antibody H1M6718N needed to inhibit the human ASIC1
current in a stably transfected HEK293 cell line expressing the
full length human ASIC1 channel (HEK/hASIC1; amino acids 1-528 of
NCBI accession number NP.sub.--001086.2).
[0121] HEK/hASIC1 cells were cultured in DMEM high glucose media,
10% fetal bovine serum, 1% non-essential amino acids and 500
.mu.g/mL Geneticin.RTM. (Invitrogen, #10131). On the day of the
recordings, cells were harvested with Detachin cell detachment
solution (Genlantis, San Diego, Calif., #T100100), centrifuged, and
resuspended in 500 .mu.L extracellular buffer solution (NaCl 140
mM, KCl 4 mM, MgCl.sub.2 1 mM, CaCl.sub.2 2 mM, glucose 5 mM and
HEPES 10 mM, pH 7.4 with NaOH). The cell suspension was then loaded
on the Port-a-Patch.
[0122] Cells were first perfused with extracellular buffer at pH
7.4 containing 0.1% (w/v) bovine serum albumin for about 5 minutes
to stabilize the patch. Then, the human ASIC1 current was elicited
for three seconds by the addition of the extracellular buffer
adjusted to pH 6.0 while cells were maintained at a holding
potential of -80 mV. The human ASIC1 current was elicited 3 times
(2 minutes apart) in pH 6.0 extracellular buffer and 3 times in pH
6.0 extracellular buffer containing either 100 nM of an isotype
control antibody or 10, 3, 1, 0.8 or 0.6 nM of the anti-ASIC1
antibody H1M6718N. Thirty pM of amiloride in pH 6 extracellular
buffer was added after completing the pH-stimulated measurements to
demonstrate that the cells were responsive through the duration of
the assay. The composition of the intracellular recording solution
was CsF 120 mM, NaCl.sub.2 15 mM, EGTA 10 mM and HEPES 10 mM;
adjusted to pH 7.3 with CsOH.
[0123] Channel blocking was measured as percent inhibition of
current flux in the presence of anti-ASIC1 antibody relative to
current flux before application of the antibody. This was averaged
over multiple blocking experiments.
[0124] The percentage of blockade of the human ASIC1 current by 10,
3, 1, 0.8 and 0.6 nM of H1M6718N is summarized in Table 10.
TABLE-US-00010 TABLE 10 Percent Inhibition of Human ASIC1 Current
by An Anti-ASIC1 Antibody At Various Concentrations Antibody %
Current Number of concentration Inhibition .+-. Antibody wells
tested (nM) SEM H1M6718N 3 10 94 .+-. 1 3 3 86 .+-. 7 4 1 76 .+-. 6
3 0.8 33 .+-. 6 4 0.6 17 .+-. 9 Isotype control 3 100 0
[0125] H1M6718N showed a dose-dependent inhibition of human ASIC1
current with a calculated IC.sub.50 of 860 pM, while the isotype
control antibody showed no inhibition of the current at a
concentration of 100 nM.
Example 7
An Anti-ASIC1 Antibody Reduces Visceral Pain Responses in a Mouse
Model
[0126] In this example, the ability of the anti-ASIC1 antibody
H1M6718N to attenuate visceral pain in a model of acetic acid
induced abdominal constrictions was assessed. Wild-type C57BL/6
mice from Jackson Laboratory (Bar Harbor, Me.) were used in this
experiment. Separate cohorts of mice (n=10) received 10 mg/kg
(s.c.) of an isotype control mAb or 1 or 10 mg/kg (s.c.) of
H1M6718N. Twenty-four hours after antibody dosing all cohorts
received an intraperitoneal injection of 0.6% acetic acid, which
produced stereotypical abdominal stretching behaviors (e.g.
constrictions) that were counted by a blinded observer for up to 30
minutes post-injection. The results of this experiment, expressed
in terms of the percent change in the total number of abdominal
constrictions, are shown in Table 11 (all data are represented as
mean.+-.SEM).
TABLE-US-00011 TABLE 11 Effect of Anti-ASIC1 Antibody on Abdominal
Constrictions Induced by Acetic Acid Injection Percent Change in
Dose of Abdominal Constrictions H1M6718N Relative to Control 1
-32.06 .+-. 15.8 10 -46.57 .+-. 19.3
[0127] This example demonstrates that anti-ASIC1 antibody
(H1M6718N), which was shown to potently block acid-induced ASIC1
ion currents (see Examples 4 through 6), was effective in
alleviating acid-induced visceral pain responses in a mouse
model.
Example 8
An Anti-ASIC1 Antibody Produces Analgesia to a Noxious Mechanical
Stimulus in a Mouse Model
[0128] In this Example, the ability of an anti-ASIC1 antibody
(H1M6718N) to produce analgesia in response to noxious
pinch/pressure stimuli was assessed.
[0129] Wild-type C57BL/6 mice from Jackson Laboratory (Bar Harbor,
Me.) were used in this experiment. Separate cohorts of mice
received 1, 10, or 40 mg/kg (s.c.) of H1M6718N, or 10 mg/kg (s.c)
of an isotype control antibody. Twenty-four hours after antibody
dosing, separate cohorts (n=10) were tested for their mechanical
nociception thresholds, which were measured by the withdrawal
threshold to a pinch of the gastrocnemius muscle or the tail (Model
#2455, IITC Life Science, Woodland Hills, Calif.). Mechanical
nociception in the tail was measured in mice treated with 1 mg/kg
and 10 mg/kg of H1M6718N in addition to those treated with an
isotype control. Mechanical nociception in the gastrocnemius muscle
was measured in mice treated with 10 mg/kg and 40 mg/kg of H1M6718N
in addition to those treated with an isotype control. The results
of these experiments, expressed as withdrawal threshold to the
pinch in grams (mean.+-.SEM for each cohort of mice), are shown in
FIG. 1, panels A and B.
[0130] For both experiments, H1M6718N treatment resulted in a
significant increase in the withdrawal threshold at the highest
antibody dose tested (10 mg/kg in tail experiment [FIG. 1, panel A]
and 40 mg/kg in the gastrocnemius muscle experiment [FIG. 1, panel
B]) compared with the isotype control as determined by ANOVA
(p=0.0015 for the tail and 0.0228 for the gastrocnemius muscle) and
by Bonferonni post-hoc test (*=p<0.05).
Example 9
An Anti-ASIC1 Antibody Attenuates Muscle Pain in Mouse Models
[0131] In this Example, the ability of anti-ASIC1 antibodies
H1M6718N and H4H6721N2 to attenuate muscle pain resulting from
injection of either acidic saline (pH 5.5) or 3% carrageenan was
assessed. Wild-type C57BL/6 mice from Jackson Laboratory (Bar
Harbor, Me.) were used in these experiments.
[0132] In a first experiment, separate cohorts of mice received 10
mg/kg (s.c) of an isotype control antibody or 10 mg/kg (s.c.) of
H1M6718N. Twenty-four hours after antibody dosing all mice received
an intramuscular injection of acidic saline (pH 5.5) into the
gastrocnemius muscle, which produced robust primary mechanical
hyperalgesia of several days as measured by the withdrawal
threshold to a pinch of the muscle (Model #2455, IITC Life Science,
Woodland Hills, Calif.). Results are shown in FIG. 2.
[0133] In a second experiment, separate cohorts of mice received 10
mg/kg (s.c.) of an isotype control mAb; 10, or 40 mg/kg (s.c.) of
H1M6718N; or 10 or 30 mg/kg (s.c.) of H4H6721N2. Twenty-four hours
after antibody dosing all mice received an intramuscular injection
of 3% carrageenan (w/v) into the gastrocnemius muscle, which
produced robust primary mechanical hyperalgesia of several days as
measured by the withdrawal threshold to a pinch of the muscle
(Model #2455, IITC Life Science, Woodland Hills, Calif.). Results
are shown in FIGS. 3A (10 and 40 mg/kg H1M6718N) and 3B (10 and 30
mg/kg H4H6721N2).
[0134] The results of these experiments, as shown in FIGS. 2 and 3,
are expressed in terms of the percent change in the withdrawal
threshold from baseline (all data are represented as mean.+-.SEM).
For both experiments, a significant main effect of the H1M6718N
treatment was observed by repeated measures ANOVA (p=0.0363 for
acidic saline and 0.0193 for carrageenan). For the second
experiment, a significant main effect of the H1M6721N2 treatment
was observed by repeated measures ANOVA (p=0.0018). *=p<0.05 and
**=p<0.01 by Bonferonni post-hoc test for the given time point.
Thus, both antibodies demonstrate substantial efficacy in
alleviating muscle pain in the experimental systems used
herein.
Example 10
Efficacy of Anti-ASIC1 Antibody in a Model of Chemotherapy-Induced
Neuropathic-Like Pain
[0135] In this Example, the ability of the anti-ASIC1 antibody
H4M6718N to attenuate neuropathic-like pain resulting from systemic
exposure the chemotherapeutic agent taxol was assessed. Wild-type
C57BL/6 male mice from Jackson Laboratory (Bar Harbor, Me.) were
used in these experiments. After baseline behavioral testing, all
mice received a regimen of taxol (4 mg/kg, every other day for a
total of 4 doses) prior to initiating therapeutic dosing. Separate
cohorts of mice received 30 mg/kg (s.c.) of an isotype control mAb,
30 mg/kg (s.c.) of H1M6718N, or 100 mg/kg (s.c.) of gabapentin. The
antibodies were administered 24 hours prior to each weekly
behavioral test and gabapentin was administered 2 hours prior to
each weekly behavioral test. Tactile allodynia was measured in all
cohorts using von Frey fibers (#58011, Stoelting Co., Wood Dale,
Ill.) according to the up-down method of Dixon (Chaplan et al., J
Neurosci Methods. 53(1):55-63). The results of this experiment are
shown in FIG. 4 (all data are represented as mean.+-.SEM).
[0136] As illustrated in FIG. 4, a significant main effect of both
H1M6718N treatment and gabapentin treatment was observed compared
to the isotype control cohort by repeated measures ANOVA (p=0.0003
for H4H6718N, p<0.00001 for gabapentin). Thus, this Example
suggests that anti-ASIC1 antibodies of the present invention are
highly effective in alleviating chemotherapy-induced pain
responses.
[0137] Collectively, the results of the foregoing Examples support
the use of anti-ASIC1 blocking antibodies for the treatment of a
variety of pain conditions.
[0138] The present invention is not to be limited in scope by the
specific embodiments described herein. Indeed, various
modifications of the invention in addition to those described
herein will become apparent to those skilled in the art from the
foregoing description and the accompanying figures. Such
modifications are intended to fall within the scope of the appended
claims.
Sequence CWU 1
1
4011348DNAArtificial SequenceSynthetic 1caggtgcagc tggtgcagtc
tggggctgaa gtgaagaagc ctggggcctc aatgaaggtc 60tcctgcaagg cttctggata
caccttcacc atttatgata tcaactgggt gcgccaggcc 120actggacaag
ggcttgagtg gatggggtgg atgaacccta ggagtggtag cacaggctat
180tcacagaagt tccagggcag agtcaccatg accaggaaca cctccataaa
cacagccttc 240atggaactga gtagcctcag gtctgatgac acggccgtgt
attactgtgt gagagggcaa 300ctcgtcctgg gctactgggg ccagggaacc
ctggtcaccg tctcctca 3482116PRTArtificial SequenceSynthetic 2Gln Val
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15
Ser Met Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ile Tyr 20
25 30 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp
Met 35 40 45 Gly Trp Met Asn Pro Arg Ser Gly Ser Thr Gly Tyr Ser
Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser
Ile Asn Thr Ala Phe65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Asp
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg Gly Gln Leu Val Leu
Gly Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115
324DNAArtificial SequenceSynthetic 3ggatacacct tcaccattta tgat
2448PRTArtificial SequenceSynthetic 4Gly Tyr Thr Phe Thr Ile Tyr
Asp1 5 524DNAArtificial SequenceSynthetic 5atgaacccta ggagtggtag
caca 2468PRTArtificial SequenceSynthetic 6Met Asn Pro Arg Ser Gly
Ser Thr1 5 727DNAArtificial SequenceSynthetic 7gtgagagggc
aactcgtcct gggctac 2789PRTArtificial SequenceSynthetic 8Val Arg Gly
Gln Leu Val Leu Gly Tyr1 5 9339DNAArtificial SequenceSynthetic
9gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc
60atcaactgca agtccagcca gagtgttgta tacagttcca cccctaagaa ctacttagct
120tggtaccagc agaaaccagg acagcctcct aaactgctca tttactgggc
atctacccgg 180gaatccgggg tccctgaccg attcagtggc cgcgggtctg
ggacagattt cactctcacc 240atcagcagcc tgcaggctga agatgtggcg
gtttattact gtcagcaata tttttctact 300ccgtacactt ttggccaggg
gaccaagctg gagatcaaa 33910113PRTArtificial SequenceSynthetic 10Asp
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1 5 10
15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Val Tyr Ser
20 25 30 Ser Thr Pro Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Arg Gly Ser Gly
Thr Asp Phe Thr Leu Thr65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp
Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95 Tyr Phe Ser Thr Pro Tyr
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 100 105 110
Lys1136DNAArtificial SequenceSynthetic 11cagagtgttg tatacagttc
cacccctaag aactac 361212PRTArtificial SequenceSynthetic 12Gln Ser
Val Val Tyr Ser Ser Thr Pro Lys Asn Tyr1 5 10 139DNAArtificial
SequenceSynthetic 13tgggcatct 9143PRTArtificial SequenceSynthetic
14Trp Ala Ser1 1527DNAArtificial SequenceSynthetic 15cagcaatatt
tttctactcc gtacact 27169PRTArtificial SequenceSynthetic 16Gln Gln
Tyr Phe Ser Thr Pro Tyr Thr1 5 17348DNAArtificial SequenceSynthetic
17caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
60tcctgcaagg cttctggata caccttcacc atttatgata tcaactgggt gcgccaggcc
120actggacaag ggcttgagtg gatggggtgg atgaacccta ggagtggtag
cacaggctat 180tcacagaagt tccagggcag agtcaccatg accaggaaca
cctccataaa cacagccttc 240atggagctga gtagcctcag atctgaggac
acggccgtct attactgtgt gagagggcaa 300ctcgtcctgg gctactgggg
ccagggaacc ctggtcaccg tctcctca 34818116PRTArtificial
SequenceSynthetic 18Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Tyr Thr Phe Thr Ile Tyr 20 25 30 Asp Ile Asn Trp Val Arg Gln Ala
Thr Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Met Asn Pro Arg
Ser Gly Ser Thr Gly Tyr Ser Gln Lys Phe 50 55 60 Gln Gly Arg Val
Thr Met Thr Arg Asn Thr Ser Ile Asn Thr Ala Phe65 70 75 80 Met Glu
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95
Val Arg Gly Gln Leu Val Leu Gly Tyr Trp Gly Gln Gly Thr Leu Val 100
105 110 Thr Val Ser Ser 115 1924DNAArtificial SequenceSynthetic
19ggatacacct tcaccattta tgat 24208PRTArtificial SequenceSynthetic
20Gly Tyr Thr Phe Thr Ile Tyr Asp1 5 2124DNAArtificial
SequenceSynthetic 21atgaacccta ggagtggtag caca 24228PRTArtificial
SequenceSynthetic 22Met Asn Pro Arg Ser Gly Ser Thr1 5
2327DNAArtificial SequenceSynthetic 23gtgagagggc aactcgtcct gggctac
27249PRTArtificial SequenceSynthetic 24Val Arg Gly Gln Leu Val Leu
Gly Tyr1 5 25339DNAArtificial SequenceSynthetic 25gacatcgtga
tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60atcaactgca
agtccagcca gagtgttgta tacagttcca acactaagaa ctacttagct
120tggtaccagc agaaaccagg acagcctcct aacctgctca tttactgggc
atctacccgg 180gaatccgggg tccctgaccg attcagtggc cgcgggtctg
ggacagattt cactctcacc 240atcagcagcc tgcaggctga agatgtggcg
gtttattact gtcagcaata tttttctact 300ccgtacactt ttggccaggg
gaccaagctg gagatcaaa 33926113PRTArtificial SequenceSynthetic 26Asp
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1 5 10
15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Val Tyr Ser
20 25 30 Ser Asn Thr Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Gln 35 40 45 Pro Pro Asn Leu Leu Ile Tyr Trp Ala Ser Thr Arg
Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Arg Gly Ser Gly
Thr Asp Phe Thr Leu Thr65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp
Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95 Tyr Phe Ser Thr Pro Tyr
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 100 105 110
Lys2736DNAArtificial SequenceSynthetic 27cagagtgttg tatacagttc
caacactaag aactac 362812PRTArtificial SequenceSynthetic 28Gln Ser
Val Val Tyr Ser Ser Asn Thr Lys Asn Tyr1 5 10 299DNAArtificial
SequenceSynthetic 29tgggcatct 9303PRTArtificial SequenceSynthetic
30Trp Ala Ser1 3127DNAArtificial SequenceSynthetic 31cagcaatatt
tttctactcc gtacact 27329PRTArtificial SequenceSynthetic 32Gln Gln
Tyr Phe Ser Thr Pro Tyr Thr1 5 33348DNAArtificial SequenceSynthetic
33gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
60tcctgtgcag cctctggatt cacctttagc agctttgcca tgagctgggt ccgccaggct
120ccagggaagg gactggagtg ggtctcaggt attagtggta gtggtggtgg
cacacactac 180gcagactccg tgaagggccg gttcaccatc tccagagaca
attcgaagaa catggtgtat 240ctgcaaatga acagcctgag agccgaggac
acggccgcat attactgtgc gaaagaggcc 300tataaatggc agccctgggg
ccagggaacc ctggtcaccg tctcctca 34834116PRTArtificial
SequenceSynthetic 34Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Gly Ser
Gly Gly Gly Thr His Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ser Lys Asn Met Val Tyr65 70 75 80 Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ala Tyr Tyr Cys 85 90 95
Ala Lys Glu Ala Tyr Lys Trp Gln Pro Trp Gly Gln Gly Thr Leu Val 100
105 110 Thr Val Ser Ser 115 3524DNAArtificial SequenceSynthetic
35ggattcacct ttagcagctt tgcc 24368PRTArtificial SequenceSynthetic
36Gly Phe Thr Phe Ser Ser Phe Ala1 5 3724DNAArtificial
SequenceSynthetic 37attagtggta gtggtggtgg caca 24388PRTArtificial
SequenceSynthetic 38Ile Ser Gly Ser Gly Gly Gly Thr1 5
3927DNAArtificial SequenceSynthetic 39gcgaaagagg cctataaatg gcagccc
27409PRTArtificial SequenceSynthetic 40Ala Lys Glu Ala Tyr Lys Trp
Gln Pro1 5 41321DNAArtificial SequenceSynthetic 41gacatccaga
tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcatc 60atcacttgcc
gggccagtca gaggattagt agctggttgg cctggtatca acagaaacca
120gggaaagccc ctaacctcct gatctataag gcgtctattt tagaaagtgg
ggtcccatca 180aggttcagcg gcagtggatc tgggacagaa ttcactctca
ccatcagcag cctgcagcct 240gatgattttg caacttatta ctgccaacag
tataatagtt attcgtacac ttttggccag 300gggaccaaac tggagatcaa a
32142107PRTArtificial SequenceSynthetic 42Asp Ile Gln Met Thr Gln
Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Ile
Ile Thr Cys Arg Ala Ser Gln Arg Ile Ser Ser Trp 20 25 30 Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45
Tyr Lys Ala Ser Ile Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser
Tyr Ser Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 4318DNAArtificial SequenceSynthetic 43cagaggatta gtagctgg
18446PRTArtificial SequenceSynthetic 44Gln Arg Ile Ser Ser Trp1 5
459DNAArtificial SequenceSynthetic 45aaggcgtct 9463PRTArtificial
SequenceSynthetic 46Lys Ala Ser1 4727DNAArtificial
SequenceSynthetic 47caacagtata atagttattc gtacact
27489PRTArtificial SequenceSynthetic 48Gln Gln Tyr Asn Ser Tyr Ser
Tyr Thr1 5 49348DNAArtificial SequenceSynthetic 49gaggtgcagc
tgttggcgtc tgggggaggc ttggtacaga ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt cacctttagt agctttgcca tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcaggt attagtggta gtggtggtag
cacatactac 180gcagactccg tgaagggccg gttcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
acggccgcat attattgtgc gaaagaggcc 300tataaatggc agccctgggg
ccagggaatc cgggtcaccg tctcctca 34850116PRTArtificial
SequenceSynthetic 50Glu Val Gln Leu Leu Ala Ser Gly Gly Gly Leu Val
Gln Thr Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Gly Ser
Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80 Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ala Tyr Tyr Cys 85 90 95
Ala Lys Glu Ala Tyr Lys Trp Gln Pro Trp Gly Gln Gly Ile Arg Val 100
105 110 Thr Val Ser Ser 115 5124DNAArtificial SequenceSynthetic
51ggattcacct ttagtagctt tgcc 24528PRTArtificial SequenceSynthetic
52Gly Phe Thr Phe Ser Ser Phe Ala1 5 5324DNAArtificial
SequenceSynthetic 53attagtggta gtggtggtag caca 24548PRTArtificial
SequenceSynthetic 54Ile Ser Gly Ser Gly Gly Ser Thr1 5
5527DNAArtificial SequenceSynthetic 55gcgaaagagg cctataaatg gcagccc
27569PRTArtificial SequenceSynthetic 56Ala Lys Glu Ala Tyr Lys Trp
Gln Pro1 5 57321DNAArtificial SequenceSynthetic 57gacatccaga
tgacccagtc tccttccacc ctgtctgctt ctgtgggaga cagagtcacc 60atcacttgcc
gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca
120gggaaagccc ctaacctcct gatctataag acgtctaatt tagaaagtgg
ggtcccatca 180aggttcagcg gcagtggatc tgggacagaa ttcactctca
ccatcagcag cctgcagcct 240gatgattttg caacttatta ctgccaacag
tataatagtt attcgtacac ttttggccag 300gggaccaagc tggagatcaa a
32158107PRTArtificial SequenceSynthetic 58Asp Ile Gln Met Thr Gln
Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 20 25 30 Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45
Tyr Lys Thr Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser
Tyr Ser Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 5918DNAArtificial SequenceSynthetic 59cagagtatta gtagctgg
18606PRTArtificial SequenceSynthetic 60Gln Ser Ile Ser Ser Trp1 5
619DNAArtificial SequenceSynthetic 61aagacgtct 9623PRTArtificial
SequenceSynthetic 62Lys Thr Ser1 6327DNAArtificial
SequenceSynthetic 63caacagtata atagttattc gtacact
27649PRTArtificial SequenceSynthetic 64Gln Gln Tyr Asn Ser Tyr Ser
Tyr Thr1 5 65366DNAArtificial SequenceSynthetic 65gaggtgcagc
tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgaaactc 60tcctgtgcag
cctctggatt cacctttagt agcttttgga tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtggccaat ataaagcaaa atggaagtga
gacatactat 180gtggactctg tgaagggccg attcaccatc tccagagaca
acaccaagaa ctcactgtat 240ctgcaaatga acagcctgag agccgaggac
acggctatat attactgtgc gagagggggg 300cggatacagc tatggtctag
ctggttcgac ccctggggcc agggaaccct ggtcaccgtc 360tcctca
36666122PRTArtificial SequenceSynthetic 66Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Lys Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Trp Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ala Asn Ile Lys Gln Asn Gly Ser Glu Thr Tyr Tyr Val Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Ser Leu
Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile
Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Arg Ile Gln Leu Trp Ser Ser
Trp Phe Asp Pro Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser
Ser 115 120 6724DNAArtificial SequenceSynthetic 67ggattcacct
ttagtagctt ttgg 24688PRTArtificial SequenceSynthetic 68Gly Phe Thr
Phe Ser Ser Phe Trp1
5 6924DNAArtificial SequenceSynthetic 69ataaagcaaa atggaagtga gaca
24708PRTArtificial SequenceSynthetic 70Ile Lys Gln Asn Gly Ser Glu
Thr1 5 7145DNAArtificial SequenceSynthetic 71gcgagagggg ggcggataca
gctatggtct agctggttcg acccc 457215PRTArtificial SequenceSynthetic
72Ala Arg Gly Gly Arg Ile Gln Leu Trp Ser Ser Trp Phe Asp Pro1 5 10
15 73321DNAArtificial SequenceSynthetic 73gacatccaga tgacccagtc
tccatcctcc ctgtcagcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca
gagcattaaa aactatttaa attggtatca gcagaaatca 120gggaaagccc
ctaaactcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca
180agggtcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag
tctgcaccct 240gaagattttg cagcttacta ctgtcaacag agtttcagtg
ccccgctcac tttcggcgga 300gggaccaagg tggagatcaa a
32174107PRTArtificial SequenceSynthetic 74Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Ser Ile Lys Asn Tyr 20 25 30 Leu Asn
Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Val Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu His
Pro65 70 75 80 Glu Asp Phe Ala Ala Tyr Tyr Cys Gln Gln Ser Phe Ser
Ala Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 7518DNAArtificial SequenceSynthetic 75cagagcatta aaaactat
18766PRTArtificial SequenceSynthetic 76Gln Ser Ile Lys Asn Tyr1 5
779DNAArtificial SequenceSynthetic 77gctgcatcc 9783PRTArtificial
SequenceSynthetic 78Ala Ala Ser1 7927DNAArtificial
SequenceSynthetic 79caacagagtt tcagtgcccc gctcact
27809PRTArtificial SequenceSynthetic 80Gln Gln Ser Phe Ser Ala Pro
Leu Thr1 5 81363DNAArtificial SequenceSynthetic 81gaggagctag
tgttggaatc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt catgtttagc acctatgcca tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcactt attagtggtc gtgacggtag
cacatactat 180gcagactccg tgaagggccg gttcaccatc tccagagaca
tttccaggaa cacgctctat 240ctacacttga acagcctgcg agccgaggac
acggccgtat attactgtgc gaaagataca 300gctgtggttc ctggctacgg
tttggacgtc tggggccaag ggaccacggt caccgtctcc 360tca
36382121PRTArtificial SequenceSynthetic 82Glu Glu Leu Val Leu Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Met Phe Ser Thr Tyr 20 25 30 Ala Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Leu Ile Ser Gly Arg Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Ile Ser Arg Asn Thr Leu
Tyr65 70 75 80 Leu His Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Lys Asp Thr Ala Val Val Pro Gly Tyr Gly
Leu Asp Val Trp Gly 100 105 110 Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 8324DNAArtificial SequenceSynthetic 83ggattcatgt ttagcaccta
tgcc 24848PRTArtificial SequenceSynthetic 84Gly Phe Met Phe Ser Thr
Tyr Ala1 5 8524DNAArtificial SequenceSynthetic 85attagtggtc
gtgacggtag caca 24868PRTArtificial SequenceSynthetic 86Ile Ser Gly
Arg Asp Gly Ser Thr1 5 8742DNAArtificial SequenceSynthetic
87gcgaaagata cagctgtggt tcctggctac ggtttggacg tc
428814PRTArtificial SequenceSynthetic 88Ala Lys Asp Thr Ala Val Val
Pro Gly Tyr Gly Leu Asp Val1 5 10 89321DNAArtificial
SequenceSynthetic 89gacatccaga tgacccagtc tcctgccacc ctgtctgcat
ctgtaggaga cagagtcacc 60atcacttgcc gggccagtca gactattagt aactggttgg
cctggtatca gcagagacca 120gggaaagccc ctaagctcct gatctataag
gcgtctagtt tagaaactgg ggtcccatca 180aggttcagcg gcagtggatc
tgggacagaa ttcactctca ccatcagcag cctgcagcct 240gatgattttg
caagttatta ctgccaacag tataatagtt attcgtggac gttcggccaa
300gggaccaagg tggaaatcaa a 32190107PRTArtificial SequenceSynthetic
90Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Ala Ser Val Gly1
5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Asn
Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Lys Ala Ser Ser Leu Glu Thr Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Asp Asp Phe Ala Ser Tyr Tyr
Cys Gln Gln Tyr Asn Ser Tyr Ser Trp 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Val Glu Ile Lys 100 105 9118DNAArtificial SequenceSynthetic
91cagactatta gtaactgg 18926PRTArtificial SequenceSynthetic 92Gln
Thr Ile Ser Asn Trp1 5 939DNAArtificial SequenceSynthetic
93aaggcgtct 9943PRTArtificial SequenceSynthetic 94Lys Ala Ser1
9527DNAArtificial SequenceSynthetic 95caacagtata atagttattc gtggacg
27969PRTArtificial SequenceSynthetic 96Gln Gln Tyr Asn Ser Tyr Ser
Trp Thr1 5 97363DNAArtificial SequenceSynthetic 97gaggagctag
tgttggaatc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt catgtttagc acctatgcca tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcactt attagtggtc gtgacggtaa
cacatactat 180gcagactccg tgaagggccg gttcaccatc tccagagaca
attccaggaa cacgctctat 240ctacaattga acagcctgcg agccgaggac
acggccttat attactgtgc gaaagataca 300gctgtggttc ctggctacgg
tatggacgtc tggggccaag ggaccacggt caccgtctcc 360tca
36398121PRTArtificial SequenceSynthetic 98Glu Glu Leu Val Leu Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Met Phe Ser Thr Tyr 20 25 30 Ala Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Leu Ile Ser Gly Arg Asp Gly Asn Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu
Tyr65 70 75 80 Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Thr Ala Val Val Pro Gly Tyr Gly
Met Asp Val Trp Gly 100 105 110 Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 9924DNAArtificial SequenceSynthetic 99ggattcatgt ttagcaccta
tgcc 241008PRTArtificial SequenceSynthetic 100Gly Phe Met Phe Ser
Thr Tyr Ala1 5 10124DNAArtificial SequenceSynthetic 101attagtggtc
gtgacggtaa caca 241028PRTArtificial SequenceSynthetic 102Ile Ser
Gly Arg Asp Gly Asn Thr1 5 10342DNAArtificial SequenceSynthetic
103gcgaaagata cagctgtggt tcctggctac ggtatggacg tc
4210414PRTArtificial SequenceSynthetic 104Ala Lys Asp Thr Ala Val
Val Pro Gly Tyr Gly Met Asp Val1 5 10 105321DNAArtificial
SequenceSynthetic 105gacatccaga tgacccagtc tcctgccacc ctgtctgcat
ctgtaggaga cagagtcacc 60atcacttgcc gggccagtca gactattagt aactggttgg
cctggtatca gcagagacca 120gggaaagccc ctaagctcct gatctataag
gcgtctagtt tagaaactgg ggtcccatca 180aggttcagcg gcagtggatc
tgggacagaa ttcactctca ccatcagcag cctgcagcct 240gatgattttg
caagttatta ctgccaacag tataatagtt attcgtggac gttcggccaa
300gggaccaagg tggaaatcaa a 321106107PRTArtificial SequenceSynthetic
106Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Ala Ser Val Gly1
5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Asn
Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Lys Ala Ser Ser Leu Glu Thr Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Asp Asp Phe Ala Ser Tyr Tyr
Cys Gln Gln Tyr Asn Ser Tyr Ser Trp 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Val Glu Ile Lys 100 105 10718DNAArtificial
SequenceSynthetic 107cagactatta gtaactgg 181086PRTArtificial
SequenceSynthetic 108Gln Thr Ile Ser Asn Trp1 5 1099DNAArtificial
SequenceSynthetic 109aaggcgtct 91103PRTArtificial SequenceSynthetic
110Lys Ala Ser1 11127DNAArtificial SequenceSynthetic 111caacagtata
atagttattc gtggacg 271129PRTArtificial SequenceSynthetic 112Gln Gln
Tyr Asn Ser Tyr Ser Trp Thr1 5 113366DNAArtificial
SequenceSynthetic 113gaggtgcagc tggtggagtc tgggggaggc ttggtccagc
ctggggggtc cctgaaactc 60tcctgtgcag cctctggatt cacctttagt agcttttgga
tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg ggtggccaat
ataaagcaaa atggaagtga gacatactat 180gtggactctg tgaagggccg
attcaccatc tccagagaca acaccaagaa ctcactgtat 240ctgcaaatga
acagcctgag agccgaggac acggctatat attactgtgc gagagggggg
300cggatacagc tatggtctag ctggttcgac ccctggggcc agggaaccct
ggtcaccgtc 360tcctca 366114122PRTArtificial SequenceSynthetic
114Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Phe 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asn Gly Ser Glu Thr Tyr
Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Thr Lys Asn Ser Leu Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Arg
Ile Gln Leu Trp Ser Ser Trp Phe Asp Pro Trp 100 105 110 Gly Gln Gly
Thr Leu Val Thr Val Ser Ser 115 120 11524DNAArtificial
SequenceSynthetic 115ggattcacct ttagtagctt ttgg 241168PRTArtificial
SequenceSynthetic 116Gly Phe Thr Phe Ser Ser Phe Trp1 5
11724DNAArtificial SequenceSynthetic 117ataaagcaaa atggaagtga gaca
241188PRTArtificial SequenceSynthetic 118Ile Lys Gln Asn Gly Ser
Glu Thr1 5 11945DNAArtificial SequenceSynthetic 119gcgagagggg
ggcggataca gctatggtct agctggttcg acccc 4512015PRTArtificial
SequenceSynthetic 120Ala Arg Gly Gly Arg Ile Gln Leu Trp Ser Ser
Trp Phe Asp Pro1 5 10 15 121321DNAArtificial SequenceSynthetic
121gccatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga
cagagtcacc 60attacttgcc gggcaagtca gggcattagc aatgatttag gctggtatca
gcagaaacca 120gggaaagccc ctaaactcct gatctatggt gcatccagtt
tacaaactgg ggtcccatca 180aggttcagcg gcagtggatc tggcacagat
ttcactctca ccatcagcag cctgcagcct 240gaagattttg caacttatta
ctgtctacaa gatttcaatt acccgtacac ttttggccag 300gggaccaaac
tggagatcaa a 321122107PRTArtificial SequenceSynthetic 122Ala Ile
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Asp 20
25 30 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
Ile 35 40 45 Tyr Gly Ala Ser Ser Leu Gln Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu
Gln Asp Phe Asn Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 12318DNAArtificial SequenceSynthetic
123cagggcatta gcaatgat 181246PRTArtificial SequenceSynthetic 124Gln
Gly Ile Ser Asn Asp1 5 1259DNAArtificial SequenceSynthetic
125ggtgcatcc 91263PRTArtificial SequenceSynthetic 126Gly Ala Ser1
12727DNAArtificial SequenceSynthetic 127ctacaagatt tcaattaccc
gtacact 271289PRTArtificial SequenceSynthetic 128Leu Gln Asp Phe
Asn Tyr Pro Tyr Thr1 5 129348DNAArtificial SequenceSynthetic
129gaggtgcagc tgttggcgtc tgggggaggc ttggtacagc ctggggggtc
cctgagactc 60tcctgtgcag cctctggatt cacctttagt agctttgcca tgagctgggt
ccgccaggct 120ccagggaagg ggctggagtg ggtctcaggt attagtggta
gtggtgttag cacatactac 180gcagactccg tgaagggccg gttcaccatc
tccagagaca attccaagaa cacgctgtat 240ctgcaaatga acagcctgag
agccgaggac acggccgcat attattgtgc gaaagaggcc 300tataaatggc
agccctgggg ccagggaatc cgggtcaccg tctcctca 348130116PRTArtificial
SequenceSynthetic 130Glu Val Gln Leu Leu Ala Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Gly
Ser Gly Val Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ala Tyr Tyr Cys 85 90
95 Ala Lys Glu Ala Tyr Lys Trp Gln Pro Trp Gly Gln Gly Ile Arg Val
100 105 110 Thr Val Ser Ser 115 13124DNAArtificial
SequenceSynthetic 131ggattcacct ttagtagctt tgcc 241328PRTArtificial
SequenceSynthetic 132Gly Phe Thr Phe Ser Ser Phe Ala1 5
13324DNAArtificial SequenceSynthetic 133attagtggta gtggtgttag caca
241348PRTArtificial SequenceSynthetic 134Ile Ser Gly Ser Gly Val
Ser Thr1 5 13527DNAArtificial SequenceSynthetic 135gcgaaagagg
cctataaatg gcagccc 271369PRTArtificial SequenceSynthetic 136Ala Lys
Glu Ala Tyr Lys Trp Gln Pro1 5 137321DNAArtificial
SequenceSynthetic 137gacatccaga tgacccagtc tccttccacc ctgtctgcat
ctgtgggaga cagagtcacc 60atcacttgcc gggccagtca gagtattagt agctggttgg
cctggtatca gcagaaacca 120gggaaagccc ctaagctcct aatctataag
gcgtctaatt tagaaagtgg ggtcccatca 180aggttcagcg gcagtggatc
tgggacagaa ttcactctca ccatcagcag cctgcagcct 240gatgattttg
caacttatta ctgccaacag tataatagtt attcgtacac ttttggccag
300gggaccaagc tggagatcaa a 321138107PRTArtificial SequenceSynthetic
138Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1
5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser
Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Lys Ala Ser
Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
13918DNAArtificial SequenceSynthetic 139cagagtatta gtagctgg
181406PRTArtificial SequenceSynthetic 140Gln Ser Ile Ser Ser Trp1 5
1419DNAArtificial SequenceSynthetic 141aaggcgtct 91423PRTArtificial
SequenceSynthetic 142Lys Ala Ser1 14327DNAArtificial
SequenceSynthetic 143caacagtata atagttattc gtacact
271449PRTArtificial SequenceSynthetic 144Gln Gln Tyr Asn Ser Tyr
Ser Tyr Thr1 5 145348DNAArtificial SequenceSynthetic 145gaggtgcagc
tgttggcgtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggatt cacctttagt agctttgcca tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcaggt attagtggta gtggtgttag
cacatactac 180gcagactccg tgaagggccg gttcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
acggccgcat attattgtgc gaaagaggcc 300tataaatggc agccctgggg
ccagggaacc ctggtcaccg tctcctca 348146116PRTArtificial
SequenceSynthetic 146Glu Val Gln Leu Leu Ala Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Gly
Ser Gly Val Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ala Tyr Tyr Cys 85 90
95 Ala Lys Glu Ala Tyr Lys Trp Gln Pro Trp Gly Gln Gly Thr Leu Val
100 105 110 Thr Val Ser Ser 115 14724DNAArtificial
SequenceSynthetic 147ggattcacct ttagtagctt tgcc 241488PRTArtificial
SequenceSynthetic 148Gly Phe Thr Phe Ser Ser Phe Ala1 5
14924DNAArtificial SequenceSynthetic 149attagtggta gtggtgttag caca
241508PRTArtificial SequenceSynthetic 150Ile Ser Gly Ser Gly Val
Ser Thr1 5 15127DNAArtificial SequenceSynthetic 151gcgaaagagg
cctataaatg gcagccc 271529PRTArtificial SequenceSynthetic 152Ala Lys
Glu Ala Tyr Lys Trp Gln Pro1 5 153321DNAArtificial
SequenceSynthetic 153gacatccaga tgacccagtc tccttccacc ctgtctgcat
ctgtgggaga cagagtcacc 60atcacttgcc gggccagtca gagtattagt agctggttgg
cctggtatca gcagaaacca 120gggaaagccc ctaagctcct aatctataag
gcgtctaatt tagaaagtgg ggtcccatca 180aggttcagcg gcagtggatc
tgggacagaa ttcactctca ccatcagcag cctgcagcct 240gatgattttg
caacttatta ctgccaacag tataatagtt attcgtacac ttttggccag
300gggaccaagc tggagatcaa a 321154107PRTArtificial SequenceSynthetic
154Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1
5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser
Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Lys Ala Ser Asn Leu Glu Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Asp Asp Phe Ala Thr Tyr Tyr
Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 15518DNAArtificial
SequenceSynthetic 155cagagtatta gtagctgg 181566PRTArtificial
SequenceSynthetic 156Gln Ser Ile Ser Ser Trp1 5 1579DNAArtificial
SequenceSynthetic 157aaggcgtct 91583PRTArtificial SequenceSynthetic
158Lys Ala Ser1 15927DNAArtificial SequenceSynthetic 159caacagtata
atagttattc gtacact 271609PRTArtificial SequenceSynthetic 160Gln Gln
Tyr Asn Ser Tyr Ser Tyr Thr1 5 161363DNAArtificial
SequenceSynthetic 161gaggtgcagc tgttggagtc tgggggggtc ttggtacagc
ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caattttaac aactatgaca
tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg ggtctcagtc
attagtgcaa gtggtcgtaa cacatactac 180gcagactccg tgaagggccg
gttcaccatc tccagagaca attccaagat cagtctgtat 240ctgcaaatga
acagcctgag acccgaggac acggccgtat attactgtgc gaaagatcac
300ctcgtccact actactacgg tatggacgtc tggggccaag ggaccacggt
caccgtctcc 360tct 363162121PRTArtificial SequenceSynthetic 162Glu
Val Gln Leu Leu Glu Ser Gly Gly Val Leu Val Gln Pro Gly Gly1 5 10
15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Asn Tyr
20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45 Ser Val Ile Ser Ala Ser Gly Arg Asn Thr Tyr Tyr
Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ser Lys Ile Ser Leu Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp His Leu Val
His Tyr Tyr Tyr Gly Met Asp Val Trp Gly 100 105 110 Gln Gly Thr Thr
Val Thr Val Ser Ser 115 120 16324DNAArtificial SequenceSynthetic
163ggattcaatt ttaacaacta tgac 241648PRTArtificial SequenceSynthetic
164Gly Phe Asn Phe Asn Asn Tyr Asp1 5 16524DNAArtificial
SequenceSynthetic 165attagtgcaa gtggtcgtaa caca 241668PRTArtificial
SequenceSynthetic 166Ile Ser Ala Ser Gly Arg Asn Thr1 5
16742DNAArtificial SequenceSynthetic 167gcgaaagatc acctcgtcca
ctactactac ggtatggacg tc 4216814PRTArtificial SequenceSynthetic
168Ala Lys Asp His Leu Val His Tyr Tyr Tyr Gly Met Asp Val1 5 10
169336DNAArtificial SequenceSynthetic 169gatattatga tgactcagtc
tccactctcc ctgtccgtca cccctggaga gccggcctcc 60atctcctgca ggtctagtca
gagcctcctg catagtaatg gatacaacta tttggattgg 120tacctccaga
agtcaggaca gtctccacac ctcctgatct atttgggttc taatcgggcc
180tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac
actgaaaatc 240agcagagtgg aggctgagga tggtggggtt tattactgca
tgcaagctct acaaactcct 300cggacgttcg gccaagggac caaggtggaa atcaaa
336170112PRTArtificial SequenceSynthetic 170Asp Ile Met Met Thr Gln
Ser Pro Leu Ser Leu Ser Val Thr Pro Gly1 5 10 15 Glu Pro Ala Ser
Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly
Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Ser Gly Gln Ser 35 40 45
Pro His Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50
55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp Gly Gly Val Tyr Tyr Cys
Met Gln Ala 85 90 95 Leu Gln Thr Pro Arg Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys 100 105 110 17133DNAArtificial
SequenceSynthetic 171cagagcctcc tgcatagtaa tggatacaac tat
3317211PRTArtificial SequenceSynthetic 172Gln Ser Leu Leu His Ser
Asn Gly Tyr Asn Tyr1 5 10 1739DNAArtificial SequenceSynthetic
173ttgggttct 91743PRTArtificial SequenceSynthetic 174Leu Gly Ser1
17527DNAArtificial SequenceSynthetic 175atgcaagctc tacaaactcc
tcggacg 271769PRTArtificial SequenceSynthetic 176Met Gln Ala Leu
Gln Thr Pro Arg Thr1 5 177363DNAArtificial SequenceSynthetic
177gaggaccgag tgttggaatc tgggggaggc ttggtacagc ctggggggtc
cctgagactc 60tcctgtgcag cctctggatt catgtttagc agctatgcca tgagctgggt
ccgccaggct 120ccagggaagg ggctggagtg ggtctcactt attagtggtc
gtgacggtaa cacatactat 180gcagactccg tgaagggccg gttcaccatc
tccagagaca attccaggaa cacgctctat 240ctacaattga acagcctgcg
agccgaggac acggccgtat attactgtgc gaaagataca 300gctgtggttc
ctggctacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc 360tca
363178121PRTArtificial SequenceSynthetic 178Glu Asp Arg Val Leu Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Met Phe Ser Ser Tyr 20 25 30 Ala Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Leu Ile Ser Gly Arg Asp Gly Asn Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu
Tyr65 70 75 80 Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Lys Asp Thr Ala Val Val Pro Gly Tyr Gly
Met Asp Val Trp Gly 100 105 110 Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 17924DNAArtificial SequenceSynthetic 179ggattcatgt
ttagcagcta tgcc 241808PRTArtificial SequenceSynthetic 180Gly Phe
Met Phe Ser Ser Tyr Ala1 5 18124DNAArtificial SequenceSynthetic
181attagtggtc gtgacggtaa caca 241828PRTArtificial SequenceSynthetic
182Ile Ser Gly Arg Asp Gly Asn Thr1 5 18342DNAArtificial
SequenceSynthetic 183gcgaaagata cagctgtggt tcctggctac ggtatggacg tc
4218414PRTArtificial SequenceSynthetic 184Ala Lys Asp Thr Ala Val
Val Pro Gly Tyr Gly Met Asp Val1 5 10 185321DNAArtificial
SequenceSynthetic 185gacatccaga tgacccagtc tccttccacc ctgtctgcat
ctgtaggaga cagagtcacc 60atcacttgcc gggccagtca gagtattagt aactggttgg
cctggtatca gcagagacca 120gggaaagccc ctaagctcct gatctataag
gcgtctagtt tagaaagtgg ggtcccatca 180aggttcagcg gcagtggatc
tgggacagaa ttcactctca ccatcagcag cctgcagcct 240gatgattttg
caagttatta ctgccaacag tataatagtt attcgtggac gttcggccaa
300gggaccaagg tggaaatcaa a 321186107PRTArtificial SequenceSynthetic
186Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1
5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn
Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Asp Asp Phe Ala Ser Tyr Tyr
Cys Gln Gln Tyr Asn Ser Tyr Ser Trp 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Val Glu Ile Lys 100 105 18718DNAArtificial
SequenceSynthetic 187cagagtatta gtaactgg 181886PRTArtificial
SequenceSynthetic 188Gln Ser Ile Ser Asn Trp1 5 1899DNAArtificial
SequenceSynthetic 189aaggcgtct 91903PRTArtificial SequenceSynthetic
190Lys Ala Ser1 19127DNAArtificial SequenceSynthetic 191caacagtata
atagttattc gtggacg 271929PRTArtificial SequenceSynthetic 192Gln Gln
Tyr Asn Ser Tyr Ser Trp Thr1 5 193348DNAArtificial
SequenceSynthetic 193gaggtgcagc tgttggcgtc tgggggaggc ttggtacagc
ctggggggtc cctgagactc 60tcctgtgcag cctctggatt cacctttagc agctttgcca
tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg ggtctcaggt
attagtggta gtggtggtag cacatactac 180gcagactccg tgaagggccg
gttcaccatc tccagagaca attccaaaaa cacgctgtat 240ctgcaaatga
acagcctgag agccgaggac acggccgcat attactgtgc gaaagaggcc
300tataaatggc agccctgggg ccagggaatc cgggtcaccg tctcctca
348194116PRTArtificial SequenceSynthetic 194Glu Val Gln Leu Leu Ala
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ala
Tyr Tyr Cys 85 90 95 Ala Lys Glu Ala Tyr Lys Trp Gln Pro Trp Gly
Gln Gly Ile Arg Val 100 105 110 Thr Val Ser Ser 115
19524DNAArtificial SequenceSynthetic 195ggattcacct ttagcagctt tgcc
241968PRTArtificial SequenceSynthetic 196Gly Phe Thr Phe Ser Ser
Phe Ala1 5 19724DNAArtificial SequenceSynthetic 197attagtggta
gtggtggtag caca 241988PRTArtificial SequenceSynthetic 198Ile Ser
Gly Ser Gly Gly Ser Thr1 5 19927DNAArtificial SequenceSynthetic
199gcgaaagagg cctataaatg gcagccc 272009PRTArtificial
SequenceSynthetic 200Ala Lys Glu Ala Tyr Lys Trp Gln Pro1 5
201321DNAArtificial SequenceSynthetic 201gacatccaga tgacccagtc
tccttccacc ctgtctgcat ctgtgggaga cagagtctcc 60atcacttgcc gggccagtca
gagtattagt agctggttgg cctggtatca gcagaaacca 120gggaaagccc
ctaagctcct gatctataag gcgtctaatt tagacagtgg ggtcccatca
180aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag
cctgcagcct 240gatgattttg caacttatta ctgccaacag tataatagtt
attcgtacac ttttggccag 300gggaccaagc tggagatcaa a
321202107PRTArtificial SequenceSynthetic 202Asp Ile Gln Met Thr Gln
Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Ser
Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 20 25 30 Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Lys Ala Ser Asn Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser
Tyr Ser Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 20318DNAArtificial SequenceSynthetic 203cagagtatta gtagctgg
182046PRTArtificial SequenceSynthetic 204Gln Ser Ile Ser Ser Trp1 5
2059DNAArtificial SequenceSynthetic 205aaggcgtct 92063PRTArtificial
SequenceSynthetic 206Lys Ala Ser1 20727DNAArtificial
SequenceSynthetic 207caacagtata atagttattc gtacact
272089PRTArtificial SequenceSynthetic 208Gln Gln Tyr Asn Ser Tyr
Ser Tyr Thr1 5 209387DNAArtificial SequenceSynthetic 209gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc cgggggggtc cctgagactc 60tcctgtgcag
cctctggatt cacctttaga aactatgcca tgagctgggt ccgccaggct
120ccaggaaagg ggctggagtg ggtctcagct attaatggtg gtggtgatag
cacatactac 180gcagactccg tgaagggccg gttcaccatc tccagagaca
attccaagaa tacgctgtat 240ctgcaaatga acagcctgag agccgaggac
acggccgtat attactgtgc gaaagaggag 300ggagactgga actacgtggg
atatggttac tactactact
acggtatgga cgtctggggc 360caagggacca cggtcaccgt ctcctca
387210129PRTArtificial SequenceSynthetic 210Glu Val Gln Leu Leu Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Tyr 20 25 30 Ala Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ala Ile Asn Gly Gly Gly Asp Ser Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Lys Glu Glu Gly Asp Trp Asn Tyr Val Gly
Tyr Gly Tyr Tyr Tyr 100 105 110 Tyr Tyr Gly Met Asp Val Trp Gly Gln
Gly Thr Thr Val Thr Val Ser 115 120 125 Ser21124DNAArtificial
SequenceSynthetic 211ggattcacct ttagaaacta tgcc 242128PRTArtificial
SequenceSynthetic 212Gly Phe Thr Phe Arg Asn Tyr Ala1 5
21324DNAArtificial SequenceSynthetic 213attaatggtg gtggtgatag caca
242148PRTArtificial SequenceSynthetic 214Ile Asn Gly Gly Gly Asp
Ser Thr1 5 21566DNAArtificial SequenceSynthetic 215gcgaaagagg
agggagactg gaactacgtg ggatatggtt actactacta ctacggtatg 60gacgtc
6621622PRTArtificial SequenceSynthetic 216Ala Lys Glu Glu Gly Asp
Trp Asn Tyr Val Gly Tyr Gly Tyr Tyr Tyr1 5 10 15 Tyr Tyr Gly Met
Asp Val 20 217321DNAArtificial SequenceSynthetic 217gacatccaga
tgacccagtc tccatcttcc atgtctgcat ctgtaggaga cagagtcacc 60atcacttgtc
gggcgagtca gggtattagc agctggttag cctggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagcg gcagtggatc tgggacagat ttcactctca
ccatcaggag cctgcagcct 240gaagattttg caacttacta ttgtcaacag
gctaacagtt tcccgtacac ttttggccag 300gggaccaagc tggagatcaa a
321218107PRTArtificial SequenceSynthetic 218Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Met Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Ser Leu Gln
Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser
Phe Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 21918DNAArtificial SequenceSynthetic 219cagggtatta gcagctgg
182206PRTArtificial SequenceSynthetic 220Gln Gly Ile Ser Ser Trp1 5
2219DNAArtificial SequenceSynthetic 221gctgcatcc 92223PRTArtificial
SequenceSynthetic 222Ala Ala Ser1 22327DNAArtificial
SequenceSynthetic 223caacaggcta acagtttccc gtacact
272249PRTArtificial SequenceSynthetic 224Gln Gln Ala Asn Ser Phe
Pro Tyr Thr1 5 225369DNAArtificial SequenceSynthetic 225caggtgcagc
tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60tcctgtgaag
cctctggttt caccttcgga agctatggca tgcactgggt ccgccaggct
120ccaggcaagg ggctggagtg gatggcagtt atatcatatg atggaaatag
tagatactct 180gcagactccg tgaagggccg attcaccatc tccagagaca
attccaagaa tacgctgtat 240ctgcagatga acagcctgag agctgaggac
acggctctgt attactgtgc gaaagaaaat 300catatagcag ctcgtcgtcc
cggaggtctg gacgtctggg gccaagggac cacggtcacc 360gtctcctca
369226123PRTArtificial SequenceSynthetic 226Gln Val Gln Leu Val Glu
Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15 Ser Leu Arg Leu
Ser Cys Glu Ala Ser Gly Phe Thr Phe Gly Ser Tyr 20 25 30 Gly Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45
Ala Val Ile Ser Tyr Asp Gly Asn Ser Arg Tyr Ser Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Glu Asn His Ile Ala Ala Arg Arg Pro
Gly Gly Leu Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val
Ser Ser 115 120 22724DNAArtificial SequenceSynthetic 227ggtttcacct
tcggaagcta tggc 242288PRTArtificial SequenceSynthetic 228Gly Phe
Thr Phe Gly Ser Tyr Gly1 5 22924DNAArtificial SequenceSynthetic
229atatcatatg atggaaatag taga 242308PRTArtificial SequenceSynthetic
230Ile Ser Tyr Asp Gly Asn Ser Arg1 5 23148DNAArtificial
SequenceSynthetic 231gcgaaagaaa atcatatagc agctcgtcgt cccggaggtc
tggacgtc 4823216PRTArtificial SequenceSynthetic 232Ala Lys Glu Asn
His Ile Ala Ala Arg Arg Pro Gly Gly Leu Asp Val1 5 10 15
233321DNAArtificial SequenceSynthetic 233gacatccaga tgacccagtc
tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcgagtca
gggcattagc atttatttag cctggtatca acagaaacca 120gggaaagttc
ctaagctcct gatctatgct gcatccagtt tgcaatcagg ggtcccatct
180cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag
cctgcagcct 240gaagatgttg caacttattt ctgtcaaaac tataacattg
ccccgtggac gctcggccaa 300gggaccaagg tggaaatcaa a
321234107PRTArtificial SequenceSynthetic 234Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ile Tyr 20 25 30 Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80 Glu Asp Val Ala Thr Tyr Phe Cys Gln Asn Tyr Asn Ile
Ala Pro Trp 85 90 95 Thr Leu Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 23518DNAArtificial SequenceSynthetic 235cagggcatta gcatttat
182366PRTArtificial SequenceSynthetic 236Gln Gly Ile Ser Ile Tyr1 5
2379DNAArtificial SequenceSynthetic 237gctgcatcc 92383PRTArtificial
SequenceSynthetic 238Ala Ala Ser1 23924DNAArtificial
SequenceSynthetic 239caaaactata acattgcccc gtgg 242408PRTArtificial
SequenceSynthetic 240Gln Asn Tyr Asn Ile Ala Pro Trp1 5
241384DNAArtificial SequenceSynthetic 241gaggtgcagc tgttggagtc
tgggggaggc ttggtgcagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt
catctttacc aattatgcca tgacctggct ccgccaggct 120ccagggaagg
ggctggagtg ggtctcagct cttagtggtt ctggtggtac cacatactac
180gcagactccg tgaagggccg gttcaccacc tccagagaca attccaagaa
cactctgtat 240ctgcaaatga acagcctgag agccgaggac acggccgtct
attactgtgc gaaagatccc 300cattactatg ggtcggggaa tgattacttc
tactactacg gtttggacgt ctggggccga 360gggaccacgg tcaccgtctc ctca
384242128PRTArtificial SequenceSynthetic 242Glu Val Gln Leu Leu Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Ile Phe Thr Asn Tyr 20 25 30 Ala Met
Thr Trp Leu Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ala Leu Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Thr Ser Arg Asp Asn Ser Lys Asn Thr Leu
Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Lys Asp Pro His Tyr Tyr Gly Ser Gly Asn
Asp Tyr Phe Tyr Tyr 100 105 110 Tyr Gly Leu Asp Val Trp Gly Arg Gly
Thr Thr Val Thr Val Ser Ser 115 120 125 24324DNAArtificial
SequenceSynthetic 243ggattcatct ttaccaatta tgcc 242448PRTArtificial
SequenceSynthetic 244Gly Phe Ile Phe Thr Asn Tyr Ala1 5
24524DNAArtificial SequenceSynthetic 245cttagtggtt ctggtggtac caca
242468PRTArtificial SequenceSynthetic 246Leu Ser Gly Ser Gly Gly
Thr Thr1 5 24763DNAArtificial SequenceSynthetic 247gcgaaagatc
cccattacta tgggtcgggg aatgattact tctactacta cggtttggac 60gtc
6324821PRTArtificial SequenceSynthetic 248Ala Lys Asp Pro His Tyr
Tyr Gly Ser Gly Asn Asp Tyr Phe Tyr Tyr1 5 10 15 Tyr Gly Leu Asp
Val 20 249336DNAArtificial SequenceSynthetic 249gatattgtga
tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60atctcctgca
ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg
120tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc
taatcgggcc 180tccggggtcc ctgacaggtt cagtggcagt ggatcaggca
cagattttac actgaaaatc 240agcagagtgg aggctgagga tgttggggtt
tattactgca tgcaggctct acaaactccg 300tacacttttg gccaggggac
caagctggag atcaaa 336250112PRTArtificial SequenceSynthetic 250Asp
Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly1 5 10
15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly
Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala
Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val
Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Leu Gln Thr Pro Tyr Thr
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110
25133DNAArtificial SequenceSynthetic 251cagagcctcc tgcatagtaa
tggatacaac tat 3325211PRTArtificial SequenceSynthetic 252Gln Ser
Leu Leu His Ser Asn Gly Tyr Asn Tyr1 5 10 2539DNAArtificial
SequenceSynthetic 253ttgggttct 92543PRTArtificial SequenceSynthetic
254Leu Gly Ser1 25527DNAArtificial SequenceSynthetic 255atgcaggctc
tacaaactcc gtacact 272569PRTArtificial SequenceSynthetic 256Met Gln
Ala Leu Gln Thr Pro Tyr Thr1 5 257357DNAArtificial
SequenceSynthetic 257gaggtgcagc tggtggagtc tgggggaggt ttggtccagt
ctggggggtc cctgagactc 60tcttgtgcag cctctggatt cacctttagt agatattgga
tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg ggtggccaac
ataaaacaag atggaagtga gaaagattat 180gtggactctg tgaagggccg
attcaccatt tccagagaca acaccaagag ctcactgttt 240ctgcaaatga
atagcctgag agccgaggac acggctgtgt attactgtgc gaaggagaga
300tggaactgga acttctttga ctactggggc cagggaaccc tggtcactgt ctcctca
357258119PRTArtificial SequenceSynthetic 258Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Ser Gly Gly1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25 30 Trp Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Asp Tyr Val Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Ser Ser Leu
Phe65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Lys Glu Arg Trp Asn Trp Asn Phe Phe Asp
Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115
25924DNAArtificial SequenceSynthetic 259ggattcacct ttagtagata ttgg
242608PRTArtificial SequenceSynthetic 260Gly Phe Thr Phe Ser Arg
Tyr Trp1 5 26124DNAArtificial SequenceSynthetic 261ataaaacaag
atggaagtga gaaa 242628PRTArtificial SequenceSynthetic 262Ile Lys
Gln Asp Gly Ser Glu Lys1 5 26336DNAArtificial SequenceSynthetic
263gcgaaggaga gatggaactg gaacttcttt gactac 3626412PRTArtificial
SequenceSynthetic 264Ala Lys Glu Arg Trp Asn Trp Asn Phe Phe Asp
Tyr1 5 10 265318DNAArtificial SequenceSynthetic 265gacatccaga
tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc
gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctataag gcatctagtt tagaaagtgg
ggtcccatca 180aggttcagcg gcagtggatc tgggacagaa ttcactctca
ccatcagcag cctgcagcct 240gatgattttg caacttatta ctgccagcag
tttaatagtt attccacttt tggccagggg 300accaagctgg agatcaaa
318266106PRTArtificial SequenceSynthetic 266Asp Ile Gln Met Thr Gln
Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 20 25 30 Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser
Tyr Ser Thr 85 90 95 Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100
105 26718DNAArtificial SequenceSynthetic 267cagagtatta gtagctgg
182686PRTArtificial SequenceSynthetic 268Gln Ser Ile Ser Ser Trp1 5
2699DNAArtificial SequenceSynthetic 269aaggcatct 92703PRTArtificial
SequenceSynthetic 270Lys Ala Ser1 27124DNAArtificial
SequenceSynthetic 271cagcagttta atagttattc cact 242728PRTArtificial
SequenceSynthetic 272Gln Gln Phe Asn Ser Tyr Ser Thr1 5
273369DNAArtificial SequenceSynthetic 273gaggtgcagc tggtggagtc
tgggggagac ttaatacagc cgggggggtc cctgagactc 60tcctgtatag cctctggatt
cacctttaga ggctatgcca tgagttgggt ccgccaggct 120ccaggggagg
ggctggactg ggtctcaggt attagttctg gtggcgggaa cacatattac
180gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa
cacgctgtat 240ttgcaaatga acagtctgag agtcgaggac acggccgtat
attactgtgc gaaagacaga 300gggggtgtaa gggactttta ctacggtttg
gacgtctggg gccaggggac cacggtcacc 360gtctcctca
369274123PRTArtificial SequenceSynthetic 274Glu Val Gln Leu Val Glu
Ser Gly Gly Asp Leu Ile Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu
Ser Cys Ile Ala Ser Gly Phe Thr Phe Arg Gly Tyr 20 25 30 Ala Met
Ser Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Asp Trp Val 35 40 45
Ser Gly Ile Ser Ser Gly Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Lys Asp Arg Gly Gly
Val Arg Asp Phe Tyr Tyr Gly Leu Asp Val 100 105 110 Trp Gly Gln Gly
Thr Thr Val Thr Val Ser Ser 115 120 27524DNAArtificial
SequenceSynthetic 275ggattcacct ttagaggcta tgcc 242768PRTArtificial
SequenceSynthetic 276Gly Phe Thr Phe Arg Gly Tyr Ala1 5
27724DNAArtificial SequenceSynthetic 277attagttctg gtggcgggaa caca
242788PRTArtificial SequenceSynthetic 278Ile Ser Ser Gly Gly Gly
Asn Thr1 5 27948DNAArtificial SequenceSynthetic 279gcgaaagaca
gagggggtgt aagggacttt tactacggtt tggacgtc 4828016PRTArtificial
SequenceSynthetic 280Ala Lys Asp Arg Gly Gly Val Arg Asp Phe Tyr
Tyr Gly Leu Asp Val1 5 10 15 281321DNAArtificial SequenceSynthetic
281gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga
cagagtcacc 60atcacttgcc gggccagtca gagtatttat agttggttgg cctggtatca
gcagaaacca 120gggaaagccc ctaaactcct gatctataag gcgtctagtt
tagaaagtgg ggtcccgtca 180aggttcagcg gcagtggatc tgggacagat
ttcactctca ccatcagcag cctgcagcct 240gatgatttta caacttatta
ctgccaacaa tatcttagtt attctcggac gttcggccaa 300gggaccaagg
tggaaatcaa a 321282107PRTArtificial SequenceSynthetic 282Asp Ile
Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Ser Trp 20
25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
Ile 35 40 45 Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro65 70 75 80 Asp Asp Phe Thr Thr Tyr Tyr Cys Gln
Gln Tyr Leu Ser Tyr Ser Arg 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100 105 28318DNAArtificial SequenceSynthetic
283cagagtattt atagttgg 182846PRTArtificial SequenceSynthetic 284Gln
Ser Ile Tyr Ser Trp1 5 2859DNAArtificial SequenceSynthetic
285aaggcgtct 92863PRTArtificial SequenceSynthetic 286Lys Ala Ser1
28727DNAArtificial SequenceSynthetic 287caacaatatc ttagttattc
tcggacg 272889PRTArtificial SequenceSynthetic 288Gln Gln Tyr Leu
Ser Tyr Ser Arg Thr1 5 289378DNAArtificial SequenceSynthetic
289gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc
cctgagactc 60tcctttgcag cctctggatt cacctttgat gattatgcca tgcactgggt
ccggcaagct 120ccagggaagg gcctggagtg ggtctcaggt attagttgga
atagtggtag cataggctat 180gcggactctg tgaagggccg attcaccatc
tccagagaca acgccaagaa ctccctgtat 240ctgcaaatga acagtctgag
agctgaggac acggccttgt attactgtgc aaaagcccgt 300ggatacagct
atggttacgg ggagtactac tacggtatgg acgtctgggg ccaagggacc
360acggtcaccg tctcctca 378290126PRTArtificial SequenceSynthetic
290Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1
5 10 15 Ser Leu Arg Leu Ser Phe Ala Ala Ser Gly Phe Thr Phe Asp Asp
Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Lys Ala Arg Gly
Tyr Ser Tyr Gly Tyr Gly Glu Tyr Tyr Tyr Gly 100 105 110 Met Asp Val
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125
29124DNAArtificial SequenceSynthetic 291ggattcacct ttgatgatta tgcc
242928PRTArtificial SequenceSynthetic 292Gly Phe Thr Phe Asp Asp
Tyr Ala1 5 29324DNAArtificial SequenceSynthetic 293attagttgga
atagtggtag cata 242948PRTArtificial SequenceSynthetic 294Ile Ser
Trp Asn Ser Gly Ser Ile1 5 29557DNAArtificial SequenceSynthetic
295gcaaaagccc gtggatacag ctatggttac ggggagtact actacggtat ggacgtc
5729619PRTArtificial SequenceSynthetic 296Ala Lys Ala Arg Gly Tyr
Ser Tyr Gly Tyr Gly Glu Tyr Tyr Tyr Gly1 5 10 15 Met Asp
Val297321DNAArtificial SequenceSynthetic 297gacatccaga tgacccagtc
tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca
gagcattagc agctatttaa attggtatca gcagaaacca 120gggaaagccc
ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca
180aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag
tctgcaacct 240gaagattttg caacttacta ctgtcaacag agttacagta
ccccgtacac ttttggccag 300gggaccaagc tggagatcaa a
321298107PRTArtificial SequenceSynthetic 298Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser
Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 29918DNAArtificial SequenceSynthetic 299cagagcatta gcagctat
183006PRTArtificial SequenceSynthetic 300Gln Ser Ile Ser Ser Tyr1 5
3019DNAArtificial SequenceSynthetic 301gctgcatcc 93023PRTArtificial
SequenceSynthetic 302Ala Ala Ser1 30327DNAArtificial
SequenceSynthetic 303caacagagtt acagtacccc gtacact
273049PRTArtificial SequenceSynthetic 304Gln Gln Ser Tyr Ser Thr
Pro Tyr Thr1 5 305351DNAArtificial SequenceSynthetic 305caggtgcagc
tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60tcctgtgcag
cgtctggatt caccttcagt aactatggca tgcactgggt ccgccaggct
120ccaggcaagg ggctggagtg ggtggcagtt atattgtatg atggaagtaa
taaatactat 180acagactccg tgaagggccg attcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
acggctgtgt attactgtgc gagagataac 300tggaactctt ttgactactg
gggccaggga accctggtca ccgtctcctc a 351306117PRTArtificial
SequenceSynthetic 306Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
Val Gln Pro Gly Arg1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met His Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Leu Tyr
Asp Gly Ser Asn Lys Tyr Tyr Thr Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Ala Arg Asp Asn Trp Asn Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110 Val Thr Val Ser Ser 115 30724DNAArtificial
SequenceSynthetic 307ggattcacct tcagtaacta tggc 243088PRTArtificial
SequenceSynthetic 308Gly Phe Thr Phe Ser Asn Tyr Gly1 5
30924DNAArtificial SequenceSynthetic 309atattgtatg atggaagtaa taaa
243108PRTArtificial SequenceSynthetic 310Ile Leu Tyr Asp Gly Ser
Asn Lys1 5 31130DNAArtificial SequenceSynthetic 311gcgagagata
actggaactc ttttgactac 3031210PRTArtificial SequenceSynthetic 312Ala
Arg Asp Asn Trp Asn Ser Phe Asp Tyr1 5 10 313321DNAArtificial
SequenceSynthetic 313gacatccaga tgacccagtc tccatcctcc ctgtctgcat
ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca gagcattagc agctatttaa
attggtatca gcagaaacca 120gggaaagccc ctaagctcct gatctatact
gcatccagtt tacaaagtgg ggtcccatca 180aggttcagtg gcagtggatc
tgggacagat ttcactctca ccatcagcag tctgcaacct 240gaagattttg
caacttacta ctgtcaacag agttacacta ccccattcac tttcggccct
300gggaccaaag tggatatcaa a 321314107PRTArtificial SequenceSynthetic
314Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser
Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Thr Ala Ser Ser Leu Gln Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr
Cys Gln Gln Ser Tyr Thr Thr Pro Phe 85 90 95 Thr Phe Gly Pro Gly
Thr Lys Val Asp Ile Lys 100 105 31518DNAArtificial
SequenceSynthetic 315cagagcatta gcagctat 183166PRTArtificial
SequenceSynthetic 316Gln Ser Ile Ser Ser Tyr1 5 3179DNAArtificial
SequenceSynthetic 317actgcatcc 93183PRTArtificial SequenceSynthetic
318Thr Ala Ser1 31927DNAArtificial SequenceSynthetic 319caacagagtt
acactacccc attcact 273209PRTArtificial SequenceSynthetic 320Gln Gln
Ser Tyr Thr Thr Pro Phe Thr1 5 321375DNAArtificial
SequenceSynthetic 321gaggtgcagc tggtggagtc tgggggaggc ttggtccagc
ctggggggtc cctgagactc 60tcctgtgcag cctctggatt cacctttagt agctattgga
tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg ggtggccaac
ataaagcaag atggaagtga gaaatactat 180gtggactctg tgaagggccg
attcaccatc tccagagaca acgccaagaa ctcactgtat 240ctgcaaatga
acagcctgag agccgaggac acggctgtgt attactgtgc gagagagagg
300gtagtagtac cagctgctat accccactgg tacttcgatc tctggggccg
tggcaccctg 360gtcaccgtct cctca 375322125PRTArtificial
SequenceSynthetic 322Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln
Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Ala Arg Glu Arg Val Val Val Pro Ala Ala Ile Pro His Trp Tyr Phe
100 105 110 Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser 115
120 125 32324DNAArtificial SequenceSynthetic 323ggattcacct
ttagtagcta ttgg 243248PRTArtificial SequenceSynthetic 324Gly Phe
Thr Phe Ser Ser Tyr Trp1 5 32524DNAArtificial SequenceSynthetic
325ataaagcaag atggaagtga gaaa 243268PRTArtificial SequenceSynthetic
326Ile Lys Gln Asp Gly Ser Glu Lys1 5 32754DNAArtificial
SequenceSynthetic 327gcgagagaga gggtagtagt accagctgct ataccccact
ggtacttcga tctc 5432818PRTArtificial SequenceSynthetic 328Ala Arg
Glu Arg Val Val Val Pro Ala Ala Ile Pro His Trp Tyr Phe1 5 10 15
Asp Leu329339DNAArtificial SequenceSynthetic 329gacatcgtga
tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60atcaactgca
agtccagcca gagtgtttta tacagctcca acaataagaa ctacttagct
120tggtaccagc agaaaccagg acagcctcct aagctgctca tttactgggc
atctacccgg 180gaatccgggg tccctgaccg attcagtggc agcgggtctg
ggacagattt cactctcacc 240atcagcagcc tgcaggctga agatgtggca
gtttattact gtcagcaata ttatagtact 300cctcggacgt tcggccaagg
gaccaaggtg gaaatcaaa 339330113PRTArtificial SequenceSynthetic
330Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1
5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr
Ser 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr
Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr65 70 75 80 Ile Ser Ser Leu Gln Ala Glu
Asp Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95 Tyr Tyr Ser Thr Pro
Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110
Lys33136DNAArtificial SequenceSynthetic 331cagagtgttt tatacagctc
caacaataag aactac 3633212PRTArtificial SequenceSynthetic 332Gln Ser
Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr1 5 10 3339DNAArtificial
SequenceSynthetic 333tgggcatct 93343PRTArtificial SequenceSynthetic
334Trp Ala Ser1 33527DNAArtificial SequenceSynthetic 335cagcaatatt
atagtactcc tcggacg 273369PRTArtificial SequenceSynthetic 336Gln Gln
Tyr Tyr Ser Thr Pro Arg Thr1 5 337375DNAArtificial
SequenceSynthetic 337caggttcagc tggtgcagtc tggagctgag gtgaagaagc
ctggggcctc agtgaaggtc 60tcctgcaagg cttctggtta cacctttacc agctatggta
tcagctgggt gcgacaggcc 120cctggacaag ggcttgagtg gatgggatgg
atcagcgctt acaatggtaa cacaaactat 180gcacagaagc tccagggcag
agtcaccatg accacagaca catccacgag cacagcctac 240atggagctga
ggagcctgag atctgacgac acggccgtgt attactgtgc gagagcgtat
300tacgatattt tgactggtta ttactactac ggtatggacg tctggggcca
agggaccacg 360gtcaccgtct cctca 375338125PRTArtificial
SequenceSynthetic 338Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln
Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala
Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg
Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Met
Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Ala Arg Ala Tyr Tyr Asp Ile Leu Thr Gly Tyr Tyr Tyr Tyr Gly Met
100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115
120 125 33924DNAArtificial SequenceSynthetic 339ggttacacct
ttaccagcta tggt 243408PRTArtificial SequenceSynthetic 340Gly Tyr
Thr Phe Thr Ser Tyr Gly1 5 34124DNAArtificial SequenceSynthetic
341atcagcgctt acaatggtaa caca 243428PRTArtificial SequenceSynthetic
342Ile Ser Ala Tyr Asn Gly Asn Thr1 5 34354DNAArtificial
SequenceSynthetic 343gcgagagcgt attacgatat tttgactggt tattactact
acggtatgga cgtc 5434418PRTArtificial SequenceSynthetic 344Ala Arg
Ala Tyr Tyr Asp Ile Leu Thr Gly Tyr Tyr Tyr Tyr Gly Met1 5 10 15
Asp Val345333DNAArtificial SequenceSynthetic 345gacatccaga
tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc
aggcgagtca ggacattagc aactatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct
gatctacgat gcatccaatt tggaaacagg ggtcccatca 180aggttcagtg
gaagtggatc tgggacagat tttactttca ccatcagcag cctgcagcct
240gaagatattg caacatatta ctgtcaacag tatgataatc tccctccggg
gggttcattc 300actttcggcc ctgggaccaa agtggatatc aaa
333346111PRTArtificial SequenceSynthetic 346Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln
Pro65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn
Leu Pro Pro 85 90 95 Gly Gly Ser Phe Thr Phe Gly Pro Gly Thr Lys
Val Asp Ile Lys 100 105 110 34718DNAArtificial SequenceSynthetic
347caggacatta gcaactat 183486PRTArtificial SequenceSynthetic 348Gln
Asp Ile Ser Asn Tyr1 5 3499DNAArtificial SequenceSynthetic
349gatgcatcc 93503PRTArtificial SequenceSynthetic 350Asp Ala Ser1
35139DNAArtificial SequenceSynthetic 351caacagtatg ataatctccc
tccggggggt tcattcact 3935213PRTArtificial SequenceSynthetic 352Gln
Gln Tyr Asp Asn Leu Pro Pro Gly Gly Ser Phe Thr1 5 10
353360DNAArtificial SequenceSynthetic 353gaggtgcagc tggtggagtc
tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt
cacctttagc agttatgcca tgagctgggt ccgccaggct 120ccagggaagg
ggctggaatg ggtctcaggt cttagtggta gtggtggtag cacatactac
180gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa
cacgctgtat 240ctgcaaatga acagcctgag agccgaggac acggccgtat
attattgtgc gaaagagaaa 300tataattgga aatttcactt tgactactgg
ggccagggaa ccctggtcac cgtctcctca 360354120PRTArtificial
SequenceSynthetic 354Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Leu Ser Gly
Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Ala Lys Glu Lys Tyr Asn Trp Lys Phe His Phe Asp Tyr Trp Gly Gln
100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
35524DNAArtificial SequenceSynthetic 355ggattcacct ttagcagtta tgcc
243568PRTArtificial SequenceSynthetic 356Gly Phe Thr Phe Ser Ser
Tyr Ala1 5 35724DNAArtificial SequenceSynthetic 357cttagtggta
gtggtggtag caca 243588PRTArtificial SequenceSynthetic 358Leu Ser
Gly Ser Gly Gly Ser Thr1 5 35939DNAArtificial SequenceSynthetic
359gcgaaagaga aatataattg gaaatttcac tttgactac 3936013PRTArtificial
SequenceSynthetic 360Ala Lys Glu Lys Tyr Asn Trp Lys Phe His Phe
Asp Tyr1 5 10 361321DNAArtificial SequenceSynthetic 361gacatccaga
tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc
aggcgagtca ggacattagc aactatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctacgat gcatccaatt tggaaacagg
ggtcccatca 180aggttcagtg gaagtggatc tgggacagat tttactttca
ccatcagcag cctgcagcct 240gaagatattg caacatatta ctgtcaacag
tatgataatc tcccgctcac tttcggcgga 300gggaccaagg tggagatcaa a
321362107PRTArtificial SequenceSynthetic 362Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln
Pro65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn
Leu Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 36318DNAArtificial SequenceSynthetic 363caggacatta gcaactat
183646PRTArtificial SequenceSynthetic 364Gln Asp Ile Ser Asn Tyr1 5
3659DNAArtificial SequenceSynthetic 365gatgcatcc 93663PRTArtificial
SequenceSynthetic 366Asp Ala Ser1 36727DNAArtificial
SequenceSynthetic 367caacagtatg ataatctccc gctcact
273689PRTArtificial SequenceSynthetic 368Gln Gln Tyr Asp Asn Leu
Pro Leu Thr1 5 369354DNAArtificial SequenceSynthetic 369caggttcagc
tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg
cttctggtta cacctttacc agctatggta tcagctgggt gcgacaggcc
120cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa
cacaaactat 180gcacagaagc tccagggcag agtcaccatg accacagaca
catccacgag cacagcctac 240atggagctga ggagcctgag atctgacgac
acggccgtgt attactgtgc gagagatggg 300agctactcct ggttcgaccc
ctggggccag ggaaccctgg tcaccgtctc ctca 354370118PRTArtificial
SequenceSynthetic 370Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln
Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala
Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg
Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Met
Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Ala Arg Asp Gly Ser Tyr Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr
100 105 110 Leu Val Thr Val Ser Ser 115 37124DNAArtificial
SequenceSynthetic 371ggttacacct ttaccagcta tggt 243728PRTArtificial
SequenceSynthetic 372Gly Tyr Thr Phe Thr Ser Tyr Gly1 5
37324DNAArtificial SequenceSynthetic 373atcagcgctt acaatggtaa caca
243748PRTArtificial SequenceSynthetic 374Ile Ser Ala Tyr Asn Gly
Asn Thr1 5 37533DNAArtificial SequenceSynthetic 375gcgagagatg
ggagctactc ctggttcgac ccc 3337611PRTArtificial SequenceSynthetic
376Ala Arg Asp Gly Ser Tyr Ser Trp Phe Asp Pro1 5 10
377321DNAArtificial SequenceSynthetic 377gacatccaga tgacccagtc
tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca
gagcattagc agctatttaa attggtatca gcagaaacca 120gggaaagccc
ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca
180aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag
tctgcaacct 240gaagattttg caacttacta ctgtcaacag agttacagta
ccccgctcac tttcggcgga 300gggaccaagg tggagatcaa a
321378107PRTArtificial SequenceSynthetic 378Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser
Thr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 37918DNAArtificial SequenceSynthetic 379cagagcatta gcagctat
183806PRTArtificial SequenceSynthetic 380Gln Ser Ile Ser Ser Tyr1 5
3819DNAArtificial SequenceSynthetic 381gctgcatcc 93823PRTArtificial
SequenceSynthetic 382Ala Ala Ser1 38327DNAArtificial
SequenceSynthetic 383caacagagtt acagtacccc gctcact
273849PRTArtificial SequenceSynthetic 384Gln Gln Ser Tyr Ser Thr
Pro Leu Thr1 5 385360DNAArtificial SequenceSynthetic 385caggtgcagc
tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60acctgcactg
tctctggtgg ctccatcagt agttactact ggagctggat ccggcagccc
120ccagggaagg gactggagtg gattgggtat atctattaca gtgggagcac
caagtacaac 180ccctccctca agagtcgagt caccatatca gtagacacgt
ccaagaacca gttctccctg 240aagctgagct ctgtgaccgc cgaagacacg
gccgtgtatt actgtgggag acaaagtggg 300agctactact actacggtat
ggacgtctgg ggccaaggga ccacggtcac cgtctcctca 360386120PRTArtificial
SequenceSynthetic 386Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
Val Lys Pro Ser Glu1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser
Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln
Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr
Ser Gly Ser Thr Lys Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val
Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80 Lys
Leu Ser Ser Val Thr Ala Glu Asp Thr Ala Val Tyr Tyr Cys Gly 85 90
95 Arg Gln Ser Gly Ser Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln
100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120
38724DNAArtificial SequenceSynthetic 387ggtggctcca tcagtagtta ctac
243888PRTArtificial SequenceSynthetic 388Gly Gly Ser Ile Ser Ser
Tyr Tyr1 5 38921DNAArtificial SequenceSynthetic 389atctattaca
gtgggagcac c 213907PRTArtificial SequenceSynthetic 390Ile Tyr Tyr
Ser Gly Ser Thr1 5 39142DNAArtificial SequenceSynthetic
391gggagacaaa gtgggagcta ctactactac ggtatggacg tc
4239214PRTArtificial SequenceSynthetic 392Gly Arg Gln Ser Gly Ser
Tyr Tyr Tyr Tyr Gly Met Asp Val1 5 10 393321DNAArtificial
SequenceSynthetic 393gacatccaga tgacccagtc tccatcctcc ctgtctgcat
ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca aagcattagc agctatttaa
attggtatca gcagaaacca 120gggaaagccc ctaagctcct gatctatgct
gcatccagtt tgcaaagtgg agtcccatca 180aggttcagtg gcagtggatc
tgggacagat ttcactctca ccatcagcag tctgcaacct 240gaagattttg
caacttacta ctgtcaacag agttacagta ccccgtacac ttttggccag
300gggaccaagc tggagatcaa a 321394107PRTArtificial SequenceSynthetic
394Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser
Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr
Cys Gln Gln Ser Tyr Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 39518DNAArtificial
SequenceSynthetic 395caaagcatta gcagctat 183966PRTArtificial
SequenceSynthetic 396Gln Ser Ile Ser Ser Tyr1 5 3979DNAArtificial
SequenceSynthetic 397gctgcatcc 93983PRTArtificial SequenceSynthetic
398Ala Ala Ser1 39927DNAArtificial SequenceSynthetic 399caacagagtt
acagtacccc gtacact 274009PRTArtificial SequenceSynthetic 400Gln Gln
Ser Tyr Ser Thr Pro Tyr Thr1 5 401528PRTHomo sapiens 401Met Glu Leu
Lys Ala Glu Glu Glu Glu Val Gly Gly Val Gln Pro Val1 5 10 15 Ser
Ile Gln Ala Phe Ala Ser Ser Ser Thr Leu His Gly Leu Ala His 20 25
30 Ile Phe Ser Tyr Glu Arg Leu Ser Leu Lys Arg Ala Leu Trp Ala Leu
35 40 45 Cys Phe Leu Gly Ser Leu Ala Val Leu Leu Cys Val Cys Thr
Glu Arg 50 55 60 Val Gln Tyr Tyr Phe His Tyr His His Val Thr Lys
Leu Asp Glu Val65 70 75 80 Ala Ala Ser Gln Leu Thr Phe Pro Ala Val
Thr Leu Cys Asn Leu Asn 85 90 95 Glu Phe Arg Phe Ser Gln Val Ser
Lys Asn Asp Leu Tyr His Ala Gly 100 105 110 Glu Leu Leu Ala Leu Leu
Asn Asn Arg Tyr Glu Ile Pro Asp Thr Gln 115 120 125 Met Ala Asp Glu
Lys Gln Leu Glu Ile Leu Gln Asp Lys Ala Asn Phe 130 135 140 Arg Ser
Phe Lys Pro Lys Pro Phe Asn Met Arg Glu Phe Tyr Asp Arg145 150 155
160 Ala Gly His Asp Ile Arg Asp Met Leu Leu Ser Cys His Phe Arg Gly
165 170 175 Glu Val Cys Ser Ala Glu Asp Phe Lys Val Val Phe Thr Arg
Tyr Gly 180 185 190 Lys Cys Tyr Thr Phe Asn Ser Gly Arg Asp Gly Arg
Pro Arg Leu Lys 195 200 205 Thr Met Lys Gly Gly Thr Gly Asn Gly Leu
Glu Ile Met Leu Asp Ile 210 215 220 Gln Gln Asp Glu Tyr Leu Pro Val
Trp Gly Glu Thr Asp Glu Thr Ser225 230 235 240 Phe Glu Ala Gly Ile
Lys Val Gln Ile His Ser Gln Asp Glu Pro Pro 245 250 255 Phe Ile Asp
Gln Leu Gly Phe Gly Val Ala Pro Gly Phe Gln Thr Phe 260 265 270 Val
Ala Cys Gln Glu Gln Arg Leu Ile Tyr Leu Pro Pro Pro Trp Gly 275 280
285 Thr Cys Lys Ala Val Thr Met Asp Ser Asp Leu Asp Phe Phe Asp Ser
290 295 300 Tyr Ser Ile Thr Ala Cys Arg Ile Asp Cys Glu Thr Arg Tyr
Leu Val305 310 315 320 Glu Asn Cys Asn Cys Arg Met Val His Met Pro
Gly Asp Ala Pro Tyr 325 330 335 Cys Thr Pro Glu Gln Tyr Lys Glu Cys
Ala Asp Pro Ala Leu Asp Phe 340 345 350 Leu Val Glu Lys Asp Gln Glu
Tyr Cys Val Cys Glu Met Pro Cys Asn 355 360 365 Leu Thr Arg Tyr Gly
Lys Glu Leu Ser Met Val Lys Ile Pro Ser Lys 370 375 380 Ala Ser Ala
Lys Tyr Leu Ala Lys Lys Phe Asn Lys Ser Glu Gln Tyr385 390 395 400
Ile Gly Glu Asn Ile Leu Val Leu Asp Ile Phe Phe Glu Val Leu Asn 405
410 415 Tyr Glu Thr Ile Glu Gln Lys Lys Ala Tyr Glu Ile Ala Gly Leu
Leu 420 425 430 Gly Asp Ile Gly Gly Gln Met Gly Leu Phe Ile Gly Ala
Ser Ile Leu 435 440 445 Thr Val Leu Glu Leu Phe Asp Tyr Ala Tyr Glu
Val Ile Lys His Lys 450 455 460 Leu Cys Arg Arg Gly Lys Cys Gln Lys
Glu Ala Lys Arg Ser Ser Ala465 470 475 480 Asp Lys Gly Val Ala Leu
Ser Leu Asp Asp Val Lys Arg His Asn Pro 485 490 495 Cys Glu Ser
Leu
Arg Gly His Pro Ala Gly Met Thr Tyr Ala Ala Asn 500 505 510 Ile Leu
Pro His His Pro Ala Arg Gly Thr Phe Glu Asp Phe Thr Cys 515 520
525
* * * * *